<SEC-DOCUMENT>0001193125-22-308750.txt : 20221220
<SEC-HEADER>0001193125-22-308750.hdr.sgml : 20221220
<ACCEPTANCE-DATETIME>20221220072115
ACCESSION NUMBER:		0001193125-22-308750
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20221220
DATE AS OF CHANGE:		20221220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Terns Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001831363
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-263370
		FILM NUMBER:		221472834

	BUSINESS ADDRESS:	
		STREET 1:		1065 EAST HILLSDALE BLVD., SUITE 100
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		650-525-5535 EXT.101

	MAIL ADDRESS:	
		STREET 1:		1065 EAST HILLSDALE BLVD., SUITE 100
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d432084d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5)<BR>Registration No. 333-263370 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#c21128"><B>The information in this preliminary prospectus supplement is not complete and may be changed.
This preliminary prospectus supplement and the accompanying prospectus do not constitute an offer to sell these securities, and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.
</B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><FONT COLOR="#c21128">SUBJECT TO COMPLETION </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><FONT COLOR="#c21128">PRELIMINARY PROSPECTUS SUPPLEMENT DATED DECEMBER&nbsp;20, 2022 </FONT></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">(To
Prospectus dated March&nbsp;14, 2022) </P> <P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>$75,000,000 Shares of Common Stock </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g432084g33a01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>Terns Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are offering $75,000,000 of shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Our common stock is traded on the Nasdaq Global Select Market under the symbol &#147;TERN.&#148; On December&nbsp;19, 2022, the last reported sale price of our common
stock was $8.95. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described under the
heading &#147;<A HREF="#suptoc432084_5">Risk Factors</A>&#148; on page <FONT STYLE="white-space:nowrap">S-11</FONT> of this prospectus supplement and in the accompanying prospectus, as well as those contained in the other documents that are
incorporated by reference and any related free writing prospectus. You should carefully read this entire prospectus supplement and the accompanying prospectus, including any information incorporated by reference, before deciding whether to purchase
shares of our common stock. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>We are an &#147;emerging growth company&#148; under the federal securities laws and are subject to reduced public company
reporting requirements. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER&nbsp;SHARE</B><br><B>OF<BR>COMMON&nbsp;STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting discounts and commissions<SUP STYLE="font-size:75%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds to Terns Pharmaceuticals, Inc., before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Underwriting&#148; beginning on page <FONT STYLE="white-space:nowrap">S-21</FONT> of this prospectus supplement for additional information regarding underwriting compensation. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The underwriters may also exercise their option to purchase up to an
additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock from us, at the public offering price, less the underwriting discounts and commissions, for 30 days after the date of
this prospectus supplement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these
securities or passed upon the accuracy or adequacy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The shares of common stock will be ready for delivery on or about
December&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Joint Book-Running Managers
</I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top" COLSPAN="3"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="right"><B>Cowen</B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Bookrunner </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:14pt">
<TD VALIGN="top" ALIGN="center"><B>UBS Investment Bank</B></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I><FONT STYLE="white-space:nowrap">Co-Lead</FONT> Managers </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"><FONT STYLE="font-size:12pt"><B>Mizuho</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="right"><B>JMP&nbsp;Securities</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>A&nbsp;C<SMALL>ITIZENS</SMALL>&nbsp;C<SMALL>OMPANY</SMALL></B></P></TD></TR>
</TABLE> <P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Prospectus Supplement dated December&nbsp;&nbsp;&nbsp;&nbsp;, 2022 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc432084_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc432084_2">MARKET, INDUSTRY AND OTHER DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc432084_3">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc432084_4">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-9</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc432084_5">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-11</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc432084_6">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-12</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc432084_7">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-14</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc432084_8">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-15</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc432084_9">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-17</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc432084_10">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-21</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc432084_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-30</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc432084_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-31</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc432084_13">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-32</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#suptoc432084_14">INFORMATION INCORPORATED BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-33</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PROSPECTUS </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx432084_1">ABOUT THIS PROSPECTUS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx432084_2">WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx432084_3">ABOUT TERNS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx432084_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx432084_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx432084_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx432084_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx432084_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx432084_9">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx432084_10">GLOBAL SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx432084_11">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx432084_12">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx432084_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc432084_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus supplement is part of a registration statement that we have filed with the U.S. Securities and Exchange Commission, or the SEC, utilizing a
&#147;shelf&#148; registration process. Under this shelf registration process, we may offer from time to time various securities, of which this offering of shares of our common stock is a part. Such registration statement also includes exhibits that
provide more detail on the matters discussed in this prospectus supplement and the accompanying prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We provide information to you about this offering of
shares of our common stock in two separate documents that are bound together: (1)&nbsp;this prospectus supplement, which describes the specific details regarding this offering; and (2)&nbsp;the accompanying prospectus, which provides general
information, some of which may not apply to this offering. Generally, when we refer to this &#147;prospectus,&#148; we are referring to both documents combined. If information in this prospectus supplement is inconsistent with the accompanying
prospectus, you should rely on this prospectus supplement. However, if any statement in one of these documents is inconsistent with a statement in another document having a later date&#151;for example, a document incorporated by reference in this
prospectus supplement&#151;the statement in the document having the later date modifies or supersedes the earlier statement as our business, financial condition, results of operations and prospects may have changed since the earlier dates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have not, and the underwriters have not, authorized anyone to provide any information other than that contained in or incorporated by reference in this prospectus
supplement, the accompanying prospectus and any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any
other information that others may give you. We are not, and the underwriters are not, making an offer to sell or soliciting an offer to buy our securities in any jurisdiction where an offer or solicitation is not authorized or in which the person
making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the
documents incorporated by reference into this prospectus, and in any free writing prospectus that we may authorize for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial
condition, results of operations and prospects may have changed since those dates. You should read this prospectus supplement, the accompanying prospectus, the documents incorporated by reference into this prospectus, and any free writing prospectus
that we may authorize for use in connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the sections of this
prospectus supplement entitled &#147;Where You Can Find More Information&#148; and &#147;Information Incorporated by Reference.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are offering to sell, and
seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus and the offering of the common stock in certain jurisdictions may be restricted by law. Persons outside the
United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus outside the United States. This prospectus
does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an
offer or solicitation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When we refer to &#147;Terns,&#148; &#147;we,&#148; &#147;our,&#148; &#147;us&#148; and the &#147;Company&#148; in this prospectus, we mean
Terns Pharmaceuticals, Inc., unless otherwise specified. When we refer to &#147;you,&#148; we mean the holders of securities of the Company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Terns,&#148;
&#147;Terns Pharmaceuticals,&#148; the Terns logo and other trademarks, trade names or service marks of Terns Pharmaceuticals, Inc. appearing in this prospectus are the property of Terns Pharmaceuticals, Inc. All other trademarks, trade names and
service marks appearing in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus may be referred to without the
<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> symbols, but such references should not be construed as any indicator that their respective owners will not assert their
rights thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc432084_2"></A>MARKET, INDUSTRY AND OTHER DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus supplement, including the information incorporated by reference herein, contains estimates, projections and other information concerning our industry,
our business, and the markets for certain drugs, including data regarding the estimated size of those markets. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual
events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and
similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or
more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc432084_3"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>This summary provides a general overview of selected information and does not contain all of the information you should consider before buying our common stock.
Therefore, you should read the entire prospectus supplement, accompanying prospectus and any free writing prospectus that we have authorized for use in connection with this offering carefully, including the information incorporated by reference
herein and therein, before deciding to invest in our common stock. Investors should carefully consider the information set forth under &#147;Risk Factors&#148; beginning on page <FONT STYLE="white-space:nowrap">S-11</FONT> of this prospectus
supplement and in the documents incorporated by reference into this prospectus supplement. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Terns Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Company Overview </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical-stage biopharmaceutical company
developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and <FONT STYLE="white-space:nowrap">non-alcoholic</FONT> steatohepatitis (NASH). Our programs are based on mechanisms of action
that have achieved <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in clinical trials in indications with large unmet needs. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The most advanced product candidates in our pipeline &#150; <FONT STYLE="white-space:nowrap">TERN-701,</FONT> <FONT STYLE="white-space:nowrap">TERN-601</FONT> and <FONT
STYLE="white-space:nowrap">TERN-501</FONT> &#150; were internally discovered. <FONT STYLE="white-space:nowrap">TERN-701</FONT> is our allosteric <FONT STYLE="white-space:nowrap">BCR-ABL</FONT> tyrosine kinase inhibitor (TKI) that is in clinical
development in China for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. We intend to initiate a Phase 1 clinical trial for <FONT STYLE="white-space:nowrap">TERN-701</FONT> in the United States in the second half of
2023. <FONT STYLE="white-space:nowrap">TERN-601</FONT> is our small-molecule glucagon-like <FONT STYLE="white-space:nowrap">peptide-1</FONT> receptor <FONT STYLE="white-space:nowrap">(GLP-1R)</FONT> agonist for metabolic diseases such as obesity,
with the goal of initiating a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trial in 2023. <FONT STYLE="white-space:nowrap">TERN-501</FONT> is our highly selective thyroid hormone receptor
beta <FONT STYLE="white-space:nowrap">(THR-&szlig;)</FONT> agonist for NASH in Phase 2a development. We expect our existing cash and cash equivalents to support our operations into 2025 and be sufficient to generate three key clinical data readouts
from our three programs in CML, obesity and NASH. Additionally, we are conducting <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies exploring <FONT STYLE="white-space:nowrap">TERN-201,</FONT> our vascular adhesion <FONT
STYLE="white-space:nowrap">protein-1</FONT> <FONT STYLE="white-space:nowrap">(VAP-1)</FONT> inhibitor, in combination with immune checkpoint inhibitors for solid tumor indications, and have an ongoing discovery effort for the <FONT
STYLE="white-space:nowrap">TERN-800</FONT> series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT
STYLE="white-space:nowrap">TERN-701:</FONT> Oral, allosteric <FONT STYLE="white-space:nowrap">BCR-ABL</FONT> tyrosine kinase inhibitor for chronic myeloid leukemia </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">TERN-701</FONT> is our proprietary, oral, potent, allosteric <FONT STYLE="white-space:nowrap">BCR-ABL</FONT> TKI specifically targeting
the ABL myristoyl pocket for chronic myeloid leukemia. CML is a form of cancer that begins in the bone marrow and leads to growth of leukemic cells. CML accounts for approximately 15% of newly diagnosed cases of leukemia in adults. In the United
States, the prevalence of CML is approximately 90,000 and is expected to reach 180,000 cases by 2030. In 2022, approximately 9,000 new cases of CML will be diagnosed, with a mortality rate of 1,200 patients expected. The standard of care (SOC) for
CML includes active-site TKIs including imatinib, nilotinib, dasatinib, bosutinib and ponatinib. However, an unmet medical need remains due to (1)&nbsp;an increasing number of patients becoming refractory or intolerant to the current SOC, <FONT
STYLE="white-space:nowrap">(2)&nbsp;BCR-ABL</FONT> mutations that are difficult for active-site TKIs to treat (e.g., T315I), or (3)&nbsp;safety warnings for active-site TKIs used in CML patients who are resistant or intolerant to prior TKI therapy.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Allosteric TKIs, which bind to the myristoyl-binding pocket, represent a new treatment class for CML and have the potential to address active-site TKI
shortcomings, including <FONT STYLE="white-space:nowrap">off-target</FONT> activity and limited efficacy against active site resistance mutations. Asciminib is the only allosteric TKI that has been approved by the FDA for use in third-line CML
patients and is being evaluated in clinical trials for earlier lines of treatment. In a Phase 3 trial, asciminib was shown to be more than twice as effective as bosutinib, a second generation active-site TKI, in achieving a major molecular response
(MMR) in third-line CML patients after 96 weeks of treatment (37.6% asciminib v. 15.8% bosutinib; p=0.001). The discontinuation rate after 96 weeks due to the lack of efficacy or adverse events in patients on asciminib was nearly half of the rate of
patients on bosutinib (31.2% asciminib v. 60.5% bosutinib). </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Similar to asciminib, <FONT STYLE="white-space:nowrap">TERN-701</FONT> aims to address the limitations of active-site
TKIs with the goal of achieving improved tumor suppression through a combination of (1)&nbsp;potent activity against <FONT STYLE="white-space:nowrap">BCR-ABL</FONT> including a broad range of mutations, and (2)&nbsp;improved safety and tolerability
profiles. As CML patient survival rates and treatment durations continue to increase, physicians are seeking additional efficacious CML therapies for patients whose tolerability, <FONT STYLE="white-space:nowrap">co-morbidity</FONT> and/or drug-drug
interaction profiles change over time, limiting their available treatment options and the effectiveness of mainstay therapies. We intend to initiate a clinical trial for <FONT STYLE="white-space:nowrap">TERN-701</FONT> in the second half of 2023 in
the United States, with potential interim <FONT STYLE="white-space:nowrap">top-line</FONT> readouts from initial cohorts in 2024. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We retain all worldwide
development and commercialization rights for <FONT STYLE="white-space:nowrap">TERN-701</FONT> outside of greater China. In July 2020, Hansoh Pharmaceuticals <FONT STYLE="white-space:nowrap">in-licensed</FONT>
<FONT STYLE="white-space:nowrap">TERN-701</FONT> for development in the greater China region. <FONT STYLE="white-space:nowrap">TERN-701</FONT> is referred to by Hansoh Pharmaceuticals as <FONT STYLE="white-space:nowrap">HS-10382.</FONT> Hansoh is
responsible for all development costs in the greater China region, including the ongoing Phase 1 trial. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2022, Hansoh initiated an open-label, multicenter,
dose-escalation and expansion, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> study in chronic or accelerated phase CML patients, who are resistant or intolerant to prior active-site <FONT
STYLE="white-space:nowrap">BCR-ABL</FONT> TKI treatment. The trial is comprised of two parts, with dose escalation being conducted in Part 1 to determine the maximum tolerated or maximum applicable dose followed by dose expansion in Part 2 of the
trial, in which additional CML patients will be enrolled to receive one or more doses selected from Part 1. Part 2 of the trial will evaluate major cytogenetic response at six months as its primary endpoint, with key secondary endpoints including
molecular response, hematologic response, measures of PK and an evaluation of safety and tolerability. The Phase 1 trial for <FONT STYLE="white-space:nowrap">TERN-701,</FONT> which is conducted and funded by Hansoh in China, is illustrated below:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g432084g39a01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">TERN-601:</FONT> Oral, small-molecule glucagon-like
<FONT STYLE="white-space:nowrap">peptide-1</FONT> <FONT STYLE="white-space:nowrap">(GLP-1)</FONT> receptor agonist for obesity </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are also developing an oral
small-molecule glucagon-like <FONT STYLE="white-space:nowrap">peptide-1</FONT> receptor <FONT STYLE="white-space:nowrap">(GLP-1R)</FONT> agonist for the treatment of obesity known as <FONT STYLE="white-space:nowrap">TERN-601.</FONT> Obesity
represents a large unmet medical need, with recent studies estimating the aggregate U.S. national cost of obesity to exceed $260&nbsp;billion. While approximately 50% of Americans meet the criteria for medical obesity, only 2% of adults receive
therapies for weight loss. <FONT STYLE="white-space:nowrap">GLP-1R</FONT> agonism has many potentially beneficial effects including increased insulin secretion by the pancreas, reduced glucagon secretion in the liver, slowed gastric emptying into
the gut, increased sense of satiety in the brain and reduced inflammation. Synthetic <FONT STYLE="white-space:nowrap">GLP-1</FONT> peptides have been approved for obesity and diabetes. Semaglutide (Wegovy), a
<FONT STYLE="white-space:nowrap">GLP-1R</FONT> peptide agonist recently approved for chronic weight management in overweight or obese patients, appears to be expanding the primary care market for obesity treatment, as 75% of Wegovy patients are
receiving anti-obesity medication for the first time. However, approved synthetic <FONT STYLE="white-space:nowrap">GLP-1R</FONT> peptide agonists </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
are biologic molecules with complex manufacturing processes and may require higher doses for weight loss or NASH treatment than for management of diabetes. These
<FONT STYLE="white-space:nowrap">GLP-1R</FONT> peptide agonists also require frequent subcutaneous injections, and titration or drug holidays for management of their poor tolerability profiles. These barriers are likely to limit their widespread use
for chronic weight management, particularly if efficacious oral treatments become available. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We aim to develop small molecule, orally administered <FONT
STYLE="white-space:nowrap">GLP-1R</FONT> agonists with a convenient oral dosing schedule for the treatment of obesity. Our <FONT STYLE="white-space:nowrap">GLP-1R</FONT> agonist program has screened more than 20,000 molecular permutations through
our proprietary quantitative structure activity relationship (QSAR) model to identify several potentially suitable small-molecule scaffolds with potentially improved properties relative to other <FONT STYLE="white-space:nowrap">GLP-1R</FONT>
agonism-based approaches. We have optimized these series of compounds and identified structures that we believe are suitable for oral administration as a single-agent or in combination with other drug candidates within our pipeline, including
small-molecule GIPR modulators. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We designated a lead development candidate for our <FONT STYLE="white-space:nowrap">GLP-1R</FONT> agonist program as <FONT
STYLE="white-space:nowrap">TERN-601</FONT> in the fourth quarter of 2021. We are conducting <FONT STYLE="white-space:nowrap">IND-enabling</FONT> activities for <FONT STYLE="white-space:nowrap">TERN-601</FONT> with the goal of initiating a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trial in 2023 and receiving <FONT STYLE="white-space:nowrap">top-line</FONT> data in 2024. We expect that the Phase 1 clinical program for <FONT
STYLE="white-space:nowrap">TERN-601</FONT> will include a single ascending dose (SAD) trial in healthy volunteers and a multiple ascending dose (MAD) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT>
trial in obese healthy volunteers and/or people with Type 2 diabetes that would potentially assess changes in body weight and glycemic control parameters, such as HbA1c. We also continue to evaluate other small-molecule <FONT
STYLE="white-space:nowrap">GLP-1R</FONT> agonists that have the potential to exhibit differentiated properties from <FONT STYLE="white-space:nowrap">TERN-601</FONT> and other <FONT STYLE="white-space:nowrap">GLP-1</FONT> product candidates. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">TERN-501:</FONT> Oral, thyroid hormone receptor-beta <FONT STYLE="white-space:nowrap">(THR-&szlig;)</FONT> agonist for NASH </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">TERN-501</FONT> is an orally administered <FONT STYLE="white-space:nowrap">THR-&szlig;</FONT> agonist with high metabolic stability,
enhanced liver distribution and greater selectivity for <FONT STYLE="white-space:nowrap">THR-&szlig;</FONT> compared to other <FONT STYLE="white-space:nowrap">THR-&szlig;</FONT> agonists in development. In November 2021, we announced positive <FONT
STYLE="white-space:nowrap">top-line</FONT> data from a Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">TERN-501</FONT> in healthy volunteers with mildly elevated <FONT STYLE="white-space:nowrap">low-density</FONT> lipoprotein (LDL)
cholesterol. This Phase 1 trial included single ascending dose (SAD), multiple ascending dose (MAD) and drug-drug interaction (DDI) cohorts evaluating the safety, tolerability, pharmacodynamics and pharmacokinetics of
<FONT STYLE="white-space:nowrap">TERN-501.</FONT> In the SAD and MAD cohorts, single and multiple doses of <FONT STYLE="white-space:nowrap">TERN-501</FONT> were generally well-tolerated with a similar incidence of adverse events (AEs) across all <FONT
STYLE="white-space:nowrap">TERN-501</FONT> treatment groups and placebo. All AEs were mild to moderate with no apparent dose relationship, no treatment-emergent serious AEs and no discontinuations of study or study drug due to any AE. There were no
cardiac safety signals, no incidence of diarrhea and no differences between <FONT STYLE="white-space:nowrap">TERN-501</FONT> groups and placebo in change from baseline in heart rate, blood pressure or other vital signs. Thyroid function test results
were consistent with <FONT STYLE="white-space:nowrap">THR-&szlig;</FONT> agonists currently in clinical development, and there were no findings of clinical hyper- or hypo-thyroidism. There were no differences between placebo and any <FONT
STYLE="white-space:nowrap">TERN-501</FONT> dose group in liver function abnormalities or mean change from baseline in liver transaminases at Day 15 in the MAD cohorts. <FONT STYLE="white-space:nowrap">TERN-501</FONT> demonstrated a predictable
pharmacokinetic profile with low variability: study drug plasma exposures were linear and approximately dose-proportional with no overlap between dose strengths. Significant effects on sex hormone binding globulin (SHBG), a key pharmacodynamic
marker of <FONT STYLE="white-space:nowrap">THR-&szlig;</FONT> engagement linked to NASH histologic efficacy, were observed following treatment with <FONT STYLE="white-space:nowrap">TERN-501.</FONT> The SHBG increases observed with 14 days of <FONT
STYLE="white-space:nowrap">TERN-501</FONT> treatment were significant, dose dependent and have been associated with robust reductions in magnetic resonance imaging proton density fat fraction <FONT STYLE="white-space:nowrap">(MRI-PDFF)</FONT> and
NAFLD Activity Score in a precedent late-stage clinical NASH trial. The overall pharmacokinetic profile from this trial indicates that <FONT STYLE="white-space:nowrap">TERN-501</FONT> is well-suited for
<FONT STYLE="white-space:nowrap">co-formulation</FONT> with other small-molecule NASH agents as an oral, once-daily fixed dose combination. In the DDI cohort, the combination of <FONT STYLE="white-space:nowrap">TERN-501</FONT> and <FONT
STYLE="white-space:nowrap">TERN-101,</FONT> our liver-distributed, <FONT STYLE="white-space:nowrap">non-bile</FONT> acid FXR agonist, was well-tolerated. Preliminary pharmacokinetic results support the
<FONT STYLE="white-space:nowrap">co-administration</FONT> of <FONT STYLE="white-space:nowrap">TERN-501</FONT> and <FONT STYLE="white-space:nowrap">TERN-101</FONT> in NASH patients, with no apparent need for dose adjustment. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2022, the U.S. Food and Drug Administration (FDA) cleared our investigational new drug (IND) application for our clinical-stage combination therapy candidates
in NASH, including combinations of <FONT STYLE="white-space:nowrap">TERN-501</FONT> and <FONT STYLE="white-space:nowrap">TERN-101</FONT> as well as future studies of other potential combination therapy regimens. Under
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the IND, we are proceeding with a multicenter randomized, double-blind, placebo-controlled Phase 2a clinical trial in noncirrhotic NASH patients using a factorial design, which includes both
monotherapy and combination arms of <FONT STYLE="white-space:nowrap">TERN-501</FONT> and <FONT STYLE="white-space:nowrap">TERN-101.</FONT> This Phase 2a trial, known as the DUET trial, is expected to enroll approximately 140 adult patients with
elevated body mass index (BMI <FONT STYLE="font-family:Times New Roman">&#8805;</FONT> 25 kg/m2) and NASH with fibrosis, but not cirrhosis, based on prior liver biopsy and/or imaging criteria and clinical criteria. All patients must have liver fat
content measured by <FONT STYLE="white-space:nowrap">MRI-PDFF</FONT> of <FONT STYLE="font-family:Times New Roman">&#8805;</FONT>10%, MRI corrected T1 (cT1) relaxation time of <FONT STYLE="font-family:Times New Roman">&#8805;</FONT> 800 msec, and
meet other inclusion and exclusion criteria. The clinical trial includes a <FONT STYLE="white-space:nowrap">12-week</FONT> treatment period and a <FONT STYLE="white-space:nowrap">4-week</FONT> <FONT STYLE="white-space:nowrap">follow-up</FONT>
period. The primary endpoint will be the relative change from baseline in <FONT STYLE="white-space:nowrap">MRI-PDFF</FONT> at Week 12 for <FONT STYLE="white-space:nowrap">TERN-501</FONT> monotherapy compared with placebo. Secondary endpoints include
assessment of changes in PDFF (combination vs. placebo) and cT1 <FONT STYLE="white-space:nowrap">(TERN-501</FONT> monotherapy vs. placebo as well as <FONT STYLE="white-space:nowrap">TERN-501</FONT> and
<FONT STYLE="white-space:nowrap">TERN-101</FONT> combination vs. placebo). Dosing in the DUET trial started in July 2022, and <FONT STYLE="white-space:nowrap">top-line</FONT> data are expected in the second half of 2023. The Phase 2a DUET trial
design is illustrated in the figure below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g432084g41a01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">TERN-201:</FONT> Oral, vascular adhesion <FONT STYLE="white-space:nowrap">protein-1</FONT> <FONT
STYLE="white-space:nowrap">(VAP-1)</FONT> inhibitor in combination with immune checkpoint inhibitors for solid tumors </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">TERN-201</FONT> is a highly-selective inhibitor of <FONT STYLE="white-space:nowrap">VAP-1</FONT> that has demonstrated sustained target
engagement in clinical trials without the <FONT STYLE="white-space:nowrap">off-target</FONT> liabilities associated with other <FONT STYLE="white-space:nowrap">VAP-1</FONT> inhibitors in development. As part of our oncology pipeline development, we
are engaging in preclinical research to evaluate the use of <FONT STYLE="white-space:nowrap">TERN-201</FONT> in combination with immune checkpoint inhibitors for solid tumor indications. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">VAP-1</FONT> is an adhesion molecule and amine oxidase enzyme expressed on the surface of endothelial cells that supports rolling,
adhesion, and transmigration of certain leukocytes into sites of inflammation. <FONT STYLE="white-space:nowrap">VAP-1</FONT> has also been associated with the recruitment of certain lymphocytes to several human tumors, including hepatocellular
carcinoma and head and neck cancer, where <FONT STYLE="white-space:nowrap">VAP-1</FONT> expressed on tumor endothelium supports lymphocyte binding. Additionally, bioinformatic analyses have shown that <FONT STYLE="white-space:nowrap">VAP-1</FONT>
expression is associated with poor prognosis of glioma patients. An analysis of various human cancers revealed that <FONT STYLE="white-space:nowrap">VAP-1</FONT> expression was a negative prognostic factor in patients with colorectal, renal, and
urothelial cancers. In mouse models of melanoma and lymphoma, <FONT STYLE="white-space:nowrap">VAP-1</FONT> inhibition was also shown to decrease the number of CD11b-positive cells, which may suppress immune response, potentially resulting in the
slowing of tumor growth. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Efficacy of cancer immunotherapy utilizing immune checkpoint inhibitors such as anti-CTLA4 and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> antibodies is often diminished by underlying immunosuppressive resistance to the therapies in the tumor microenvironment. <FONT STYLE="white-space:nowrap">VAP-1</FONT> may contribute to tumor
progression through migration of such immunosuppressive myeloid cells. In a recent publication, <FONT STYLE="white-space:nowrap">VAP-1</FONT> inhibition was shown to reduce tumor growth in murine colon
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
cancer models. Furthermore, synergistic effects were observed with <FONT STYLE="white-space:nowrap">VAP-1</FONT> inhibition in combination with anti-CTLA4 or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibodies. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">TERN-800</FONT> Series: Discovery series of small-molecule
glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As part of our ongoing discovery efforts, we are evaluating a family of
small-molecule glucose-dependent insulinotropic polypeptide (GIP) receptor modulators, designated as the <FONT STYLE="white-space:nowrap">TERN-800</FONT> series, for obesity. GIP is secreted in response to nutrient ingestion to enhance
meal-stimulated insulin secretion in a glucose-dependent manner by activating its associated GIP receptor (GIPR) in pancreatic beta cells and other cells in various tissues. In preclinical studies, GIPR activation appears to reduce food intake and
promote weight loss when combined with its incretin partner <FONT STYLE="white-space:nowrap">GLP-1.</FONT> The overlapping body weight-lowering actions of both GIP and <FONT STYLE="white-space:nowrap">GLP-1</FONT> suggests that combining the actions
of these two peptide hormones may bolster glucose-lowering and appetite-suppressing effects beyond those observed with individual agents. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In a preclinical study,
two weeks of simultaneous administration of equimolar amounts of a <FONT STYLE="white-space:nowrap">GLP-1R</FONT> and a GIPR agonist reduced food intake, body weight, and fat mass in mice to a greater extent than either agent alone. Late stage dual <FONT
STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor agonists, tirzepatide (Lilly) and NNC0090-2746 (Novo Nordisk), have shown improved glycemic control compared to <FONT STYLE="white-space:nowrap">GLP-1</FONT> agonist alone, and decreased body
weight in clinical trials. Additionally, a monomolecular combination of a GIPR <FONT STYLE="white-space:nowrap">antagonist/GLP-1R</FONT> agonist, AMG 133 (Amgen), enhanced the observed weight loss in animal obesity models. In a Phase 1 clinical
study of AMG 133, a single high dose resulted in approximately 8 kilograms of weight loss. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Similar to our discovery process for
<FONT STYLE="white-space:nowrap">GLP-1,</FONT> we have synthesized small molecule ligands targeting the GIP receptor and are currently assessing their activity at relevant <FONT STYLE="white-space:nowrap">G-protein</FONT> coupled receptors. We plan
to combine GIPR modulators with <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor agonists, such as <FONT STYLE="white-space:nowrap">TERN-601,</FONT> for the treatment of obesity and metabolic diseases. We believe our small molecules have the
advantage of oral bioavailability and the ability to dose adjust to achieve an optimal response. Combining GIPR modulators with <FONT STYLE="white-space:nowrap">GLP-1</FONT> represents a promising strategy under investigation for the treatment of
obesity. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Recent Developments </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2022, we entered into a
sales agreement, or the Sales Agreement, for an &#147;at the market&#148; offering with Cowen and Company, LLC, or Cowen, relating to shares of our common stock having an aggregate offering price of up to $75.0&nbsp;million. Subsequent to
September&nbsp;30, 2022 and through the date of this prospectus supplement, we have issued 4,122,628 shares of common stock pursuant to the Sales Agreement for gross proceeds of $25.8&nbsp;million. As of the date of this prospectus supplement,
approximately $49.2&nbsp;million of shares of common stock remains available for sale under the Sales Agreement. There can be no assurance as to whether or, if so, how many or when, additional shares will be issued by us thereunder. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>About Terns </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We were incorporated under the laws of the Cayman
Islands on December&nbsp;9, 2016. On December&nbsp;29, 2020, we effected a <FONT STYLE="white-space:nowrap">de-registration</FONT> under the Cayman Islands Companies Law (2020 Revision) and a domestication under Section&nbsp;388 of the Delaware
General Corporation Law (by means of filing a certificate of domestication with the Secretary of State of Delaware), pursuant to which our jurisdiction of incorporation was changed from the Cayman Islands to the State of Delaware. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our principal executive offices are located at 1065 East Hillsdale Boulevard, Suite 100, Foster City, California 94404, and our telephone number is (650) <FONT
STYLE="white-space:nowrap">525-5535.</FONT> Our corporate website address is www.ternspharma.com. Information contained on, or accessible through, our website shall not be deemed incorporated into and is not a part of this prospectus or the
registration statement of which it forms a part. We have included our website in this prospectus solely as an inactive textual reference. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Implications of
Being an Emerging Growth Company </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We will
remain an emerging growth company until the earliest of (i)&nbsp;the last day of the fiscal year </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
following the fifth anniversary of the consummation of our initial public offering, (ii)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of at least
$1.235&nbsp;billion, (iii)&nbsp;the last day of the fiscal year in which we are deemed to be a &#147;large accelerated filer&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Securities Exchange Act of 1934, as
amended, or the Exchange Act, which would occur if the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeded $700.0&nbsp;million as of the last business day of the second fiscal quarter of such year
or (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. An emerging growth company may take advantage of specified
reduced reporting requirements and is relieved of certain other significant requirements that are otherwise generally applicable to public companies. As an emerging growth company: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We will present in this prospectus only two years of audited consolidated financial statements, plus unaudited condensed
consolidated financial statements for any interim period, and related management&#146;s discussion and analysis of financial condition and results of operations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We will avail ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the
assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We will provide less extensive disclosure about our executive compensation arrangements; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We will not require stockholder <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on executive
compensation or golden parachute arrangements. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accordingly, the information contained herein may be different than the information you receive
from our competitors that are public companies or other public companies in which you hold stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the JOBS Act provides that an emerging growth
company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would
otherwise apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards, and therefore we will not be subject to the same requirements to adopt new or revised accounting standards as other
public companies that are not emerging growth companies. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc432084_4"></A>THE OFFERING </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Common Stock Offered by Us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Underwriters&#146; Option to Purchase Additional Shares </P></TD>
<TD>The underwriters have the option to purchase up to an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, which they may exercise, from time to time, in whole or
in part, for a period of 30 days from the date of this prospectus supplement. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Common Stock Outstanding After This Offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares (or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise their option to purchase
additional shares in full). </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Use of Proceeds </P></TD>
<TD>We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows: (1)&nbsp;to advance our clinical-stage development pipeline, including the <FONT STYLE="white-space:nowrap">TERN-501,</FONT> <FONT
STYLE="white-space:nowrap">TERN-701</FONT> and <FONT STYLE="white-space:nowrap">TERN-601</FONT> clinical programs and (2)&nbsp;for working capital and general corporate purposes. See &#147;Use of Proceeds&#148; on page
<FONT STYLE="white-space:nowrap">S-14.</FONT> </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Risk Factors </P></TD>
<TD>You should read the &#147;Risk Factors&#148; section of this prospectus supplement and in the documents incorporated by reference in this prospectus supplement for a discussion of factors to consider before deciding to invest in shares of our
common stock. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Symbol on the Nasdaq Global Select Market </P></TD>
<TD>&#147;TERN&#148;. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The number of shares of common stock to be outstanding after this offering is based on 37,613,829 shares of our common stock
outstanding as of September&nbsp;30, 2022 and excludes, in each case as of September&nbsp;30, 2022 (unless otherwise indicated): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">$75.0&nbsp;million of shares of our common stock remaining available for sale by us as of September&nbsp;30, 2022 under
our &#147;at the market&#148; offering facility with Cowen, of which 4,122,628 shares of our common stock (or $25.8&nbsp;million in gross proceeds) were sold subsequent to September&nbsp;30, 2022; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">4,760,085 shares of our common stock issuable upon the exercise of stock options to purchase common stock that were
outstanding as of September&nbsp;30, 2022, with a weighted average exercise price of $8.24 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">100,880 shares of our common stock issuable upon the vesting of restricted stock units that were unvested as of
September&nbsp;30, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1,108,605 shares of our common stock reserved for issuance pursuant to future awards under our 2021 Incentive Award Plan,
as well as any automatic increases in the number of shares of our common stock reserved for future issuance under this plan; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">408,134 shares of our common stock reserved for issuance pursuant to future awards under our Employee Stock Purchase Plan,
as well as any automatic increases in the number of shares of our common stock reserved for future issuance under this plan; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1,400,000 shares of our common stock reserved for issuance pursuant to future awards under our Employee Inducement Award
Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">14,630,000 shares of our common stock issuable upon the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants with an exercise price of $0.0001 per <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, unless we specifically state otherwise, all information in this prospectus supplement assumes no
exercise of outstanding <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants or stock options or settlement of outstanding restricted stock units subsequent to September&nbsp;30, 2022. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except as otherwise indicated, all information in this prospectus supplement assumes no exercise by the underwriters of their option to purchase additional shares of
our common stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2022, we entered into the Sales Agreement for an &#147;at the market&#148; offering with Cowen relating to shares of our common stock
having an aggregate offering price of up to $75.0&nbsp;million. Subsequent to September&nbsp;30, 2022 and through the date of this prospectus supplement, we have issued 4,122,628 shares of common stock pursuant to the Sales Agreement for gross
proceeds of $25.8&nbsp;million. As of the date of this prospectus supplement, approximately $49.2&nbsp;million of shares of common stock remains available for sale under the Sales Agreement. There can be no assurance as to whether or, if so, how
many or when, additional shares will be issued by us thereunder. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc432084_5"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>You should consider carefully the risks described below and discussed under the section captioned &#147;Risk Factors&#148; contained in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, as updated by our subsequent filings under the Exchange Act, each of which is incorporated by reference in this prospectus supplement in its entirety, together with
other information in this prospectus supplement, and the information and documents incorporated by reference in this prospectus supplement, and any free writing prospectus that we have authorized for use in connection with this offering before you
make a decision to invest in our common stock. If any of the following events actually occur, our business, operating results, prospects or financial condition could be materially and adversely affected. This could cause the trading price of our
common stock to decline and you may lose all or part of your investment. The risks described below are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also affect our business
operations. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Relating to this Offering </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our management
team may invest or spend the proceeds of this offering in ways with which you may not agree or in ways which may not yield a significant return. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
management will have broad discretion over the use of proceeds from this offering. We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, (1)&nbsp;to advance our clinical-stage development
pipeline, including the <FONT STYLE="white-space:nowrap">TERN-501,</FONT> <FONT STYLE="white-space:nowrap">TERN-701</FONT> and <FONT STYLE="white-space:nowrap">TERN-601</FONT> clinical programs and (2)&nbsp;for working capital and general corporate
purposes. Our management will have considerable discretion in the application of the net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. In
particular, management may determine to prioritize resources to develop certain programs based on a variety of factors, including, among others, the receipt of clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data, changes in the
regulatory landscape, commercial potential of a program, additional financial commitments and competitive factors. The net proceeds may be used for corporate purposes that do not increase our operating results or enhance the value of our common
stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>You may experience immediate and substantial dilution in the net tangible book value per share of the common stock you purchase. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The price per share of our common stock being offered may be higher than the net tangible book value per share of our common stock outstanding prior to this offering.
Assuming aggregate proceeds of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million in this offering, and after deducting commissions and estimated aggregate offering expenses payable by us, you will suffer immediate and substantial dilution of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, representing the difference between the as adjusted net tangible book value per share of our common stock as of September&nbsp;30, 2022 after giving effect to this offering and the offering
price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. See the section entitled &#147;Dilution&#148; below for a more detailed discussion of the dilution you will incur if you purchase common stock in this offering. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>You may experience dilution as a result of future equity offerings. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In order to raise additional capital, we expect to in the future offer additional shares of our common stock or other securities convertible into or exchangeable for
our common stock. For example, on March&nbsp;14, 2022, we filed a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-263370),</FONT> covering the offering of up to
$250.0&nbsp;million of shares of common stock, preferred stock, debt securities, warrants and units. On March&nbsp;17, 2022, we filed a prospectus supplement and entered into the Sales Agreement with Cowen to sell shares of our common stock, from
time to time, with aggregate gross sales proceeds of up to $75.0&nbsp;million through an &#147;at the market&#148; offering facility under which Cowen will act as our sales agent. Pursuant to the Sales Agreement, we have sold 4,122,628 shares of our
common stock subsequent to September&nbsp;30, 2022. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in
this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock or other securities convertible into or
exchangeable for our common stock in future transactions may be higher or lower than the price per share in this offering. As of September&nbsp;30, 2022, approximately 22.4&nbsp;million shares of our common stock are subject to outstanding <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants, subject to outstanding options, issuable upon vesting of outstanding restricted stock units, or are reserved for future issuance under our equity incentive plans and are eligible for sale in the
public market to the extent permitted by the provisions of various vesting schedules and Rule 144 and Rule 701 under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc432084_6"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus supplement contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans,
objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. These statements involve
known and unknown risks, uncertainties related to the global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and other important factors that are in some cases beyond our control and may cause our actual results, performance or
achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In some
cases, you can identify forward-looking statements by terminology such as &#147;aim,&#148; &#147;anticipate,&#148; &#147;assume,&#148; &#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;due,&#148;
&#147;estimate,&#148; &#147;expect,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;objective,&#148; &#147;plan,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;positioned,&#148; &#147;seek,&#148; &#147;should,&#148;
&#147;target,&#148; &#147;will,&#148; &#147;would&#148; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking
statements include, but are not limited to, statements about: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our expectations with regard to the results of our clinical studies, preclinical studies and research and development
programs, including the timing and availability of data from such studies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing of commencement of future nonclinical studies and clinical trials and research and development programs;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our clinical and regulatory development plans; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our anticipated use of proceeds from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our expectations regarding the potential market size and size of the potential patient populations for our product
candidates and any future product candidates if approved for commercial use; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to acquire, discover, develop and advance product candidates into, and successfully complete, clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our intentions and our ability to establish collaborations and/or partnerships; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing or likelihood of regulatory filings and approvals for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our commercialization, marketing and manufacturing capabilities and expectations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our intentions with respect to the commercialization of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the pricing and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential effects of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> inflation and economic uncertainty on our
preclinical and clinical programs and business; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the implementation of our business model and strategic plans for our business and product candidates, including additional
indications which we may pursue; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope of protection we are able to establish, maintain, protect and enforce for intellectual property rights covering
our product candidates including the projected terms of patent protection; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">estimates of our expenses, future revenue, capital requirements, our needs for additional financing and our ability to
obtain additional capital and the timing of the sufficiency of our capital resources; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our future financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developments and projections relating to our competitors and our industry, including competing products; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">other risks and uncertainties, including those listed under the caption &#147;Risk Factors.&#148; </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You should read this prospectus supplement, the accompanying prospectus, and the documents incorporated by reference herein completely and with the understanding that
our actual results may differ materially from what we expect as expressed or implied by our forward-looking statements. In light of the significant risks and uncertainties to which our forward-looking statements are subject, you should not place
undue reliance on or regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all. We discuss many of these risks in greater detail in the
documents incorporated by reference herein, including under the heading &#147;Risk Factors.&#148; These forward-looking statements represent our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
estimates and assumptions only as of the dates of this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein, and any free writing
prospectus, as applicable, regardless of the time of delivery of this prospectus supplement or any sale of our securities and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether
as a result of new information, future events or otherwise after the date of this prospectus supplement. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc432084_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate that we will receive net proceeds of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, after deducting the
underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters exercise their option to purchase up to an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares in full,
we estimate that the net proceeds from the sale of the shares in this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows: (1)&nbsp;to advance our clinical-stage
development pipeline, including the <FONT STYLE="white-space:nowrap">TERN-501,</FONT> <FONT STYLE="white-space:nowrap">TERN-701</FONT> and <FONT STYLE="white-space:nowrap">TERN-601</FONT> clinical programs; and (2)&nbsp;for working capital and
general corporate purposes. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The amounts and timing of our actual expenditures will depend on numerous factors, including our research and development efforts with
respect to our product candidates, as well as the amount of cash used in our operations and the factors described under &#147;Risk Factors&#148; in this prospectus supplement, the accompanying prospectus and in the documents incorporated by
reference herein. We therefore cannot estimate with certainty the amount of net proceeds to be used for the purposes described above. We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion
in the application of the net proceeds. Pending the uses described above, we plan to invest the net proceeds, if any, from this offering in short-term, investment-grade, interest-bearing securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc432084_8"></A>DILUTION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our net tangible book value as of September&nbsp;30, 2022 was approximately $183.7&nbsp;million, or $4.88 per share. Net tangible book value per share is determined by
dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of September&nbsp;30, 2022. Dilution in net tangible book value per share represents the difference between the amount per share
paid by purchasers of shares of our common stock in this offering and the as adjusted net tangible book value per share of our common stock immediately after giving effect to this offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After giving effect to the sale of shares of our common stock at the public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share of common stock and after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of September&nbsp;30, 2022 would have been
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. This represents an immediate increase in net tangible book value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to existing stockholders and immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to new investors purchasing
our common stock in this offering at the public offering price. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table illustrates this calculation on a per share basis: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net tangible book value per share as of September&nbsp;30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase per share attributable to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">As adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dilution per share to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the underwriters exercise in full their option to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common
stock, the as adjusted net tangible book value after this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of our common stock, representing an immediate increase in net tangible book value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to existing stockholders and an immediate dilution in net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share
to new investors purchasing our common stock in this offering at the public offering price. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that outstanding
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants or options are exercised or outstanding restricted stock awards vest, investors purchasing our common stock in this offering may experience further dilution. In addition, we may choose to
raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital through the sale of equity or
convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The above discussion and table are based on
37,613,829 shares of our common stock outstanding as of September&nbsp;30, 2022 and excludes, in each case as of September&nbsp;30, 2022 (unless otherwise indicated): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">$75.0&nbsp;million of shares of our common stock remaining available for sale by us as of September&nbsp;30, 2022 under
our &#147;at the market&#148; offering facility with Cowen, of which 4,122,628 shares of our common stock (or $25.8&nbsp;million in gross proceeds) were sold subsequent to September&nbsp;30, 2022; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">4,760,085 shares of our common stock issuable upon the exercise of stock options to purchase common stock that were
outstanding as of September&nbsp;30, 2022, with a weighted average exercise price of $8.24 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">100,880 shares of our common stock issuable upon the vesting of restricted stock units that were unvested as of
September&nbsp;30, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1,108,605 shares of our common stock reserved for issuance pursuant to future awards under our 2021 Incentive Award Plan,
as well as any automatic increases in the number of shares of our common stock reserved for future issuance under this plan; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">408,134 shares of our common stock reserved for issuance pursuant to future awards under our Employee Stock Purchase Plan,
as well as any automatic increases in the number of shares of our common stock reserved for future issuance under this plan; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1,400,000 shares of our common stock reserved for issuance pursuant to future awards under our Employee Inducement Award
Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">14,630,000 shares of our common stock issuable upon the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants with an exercise price of $0.0001 per <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2022, we entered into the
Sales Agreement for an &#147;at the market&#148; offering with Cowen relating to shares of our common stock having an aggregate offering price of up to $75.0&nbsp;million. Subsequent to September&nbsp;30, 2022 and through the date of this prospectus
supplement, we have issued 4,122,628 shares of common stock pursuant to the Sales Agreement for gross proceeds of $25.8&nbsp;million. As of the date of this prospectus supplement, approximately $49.2&nbsp;million of shares of common stock remains
available for sale under the Sales Agreement. There can be no assurance as to whether or, if so, how many or when, additional shares will be issued by us thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc432084_9"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following discussion is a summary of the material U.S. federal income tax consequences to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax effects. The
effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws are not discussed. This discussion is based on the U.S. Internal Revenue Code of
1986, as amended, or the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or the IRS, in each case in effect as of the date hereof.
These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder. We
have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the purchase,
ownership and disposition of our common stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This discussion is limited to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that hold our common stock as
a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s particular circumstances, including the impact of the Medicare contribution tax on net investment income and the alternative minimum tax. In addition, it does not address consequences
relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders subject to special rules, including, without limitation: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. expatriates and former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion
transaction or other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">banks, insurance companies, and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">brokers, dealers or traders in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations that
accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors
therein); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons deemed to sell our common stock under the constructive sale provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all of the
interests of which are held by qualified foreign pension funds. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If an entity or arrangement treated as a partnership for U.S. federal income tax
purposes holds our common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership (or such other entity or arrangement) and certain determinations made at the partner
level. Accordingly, partnerships holding our common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>THIS DISCUSSION IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR
PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR
<FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Definition of a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is any beneficial owner of our common stock that is neither a
&#147;U.S. person&#148; nor an entity or arrangement treated as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">a corporation created or organized under the laws of the United States, any state thereof or the District of Columbia;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">a trust that (1)&nbsp;is subject to the primary supervision of a U.S. court and all substantial decisions of which are
subject to the control of one or more &#147;United States persons&#148; (within the meaning of Section&nbsp;7701(a)(30) of the Code), or (2)&nbsp;has a valid election in effect to be treated as a United States person for U.S. federal income tax
purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Distributions </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not currently intend
to pay any cash dividends on our common stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent
paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and first be applied against
and reduce a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in its common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described below under &#147;-Sale or Other
Taxable Disposition.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the discussion below regarding effectively connected income, dividends paid to a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty, provided the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder furnishes a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other applicable
documentation) certifying qualification for the lower treaty rate). A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate, may obtain a refund
of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding their entitlement to benefits under any applicable tax
treaties. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder are effectively connected with the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a
permanent establishment in the United States to which such dividends are attributable), the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be exempt from the U.S. federal withholding tax described above. To claim the exemption, the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must furnish to the applicable withholding agent a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> certifying that the dividends are effectively connected with the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any such effectively connected dividends will be
subject to U.S. federal income tax on a net income basis at the regular rates applicable to U.S. persons. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30%
(or such lower rate specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any
applicable tax treaties that may provide for different rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Sale or Other Taxable Disposition </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable disposition
of our common stock unless: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a
trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such gain is
attributable); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual present in the United States
for 183 days or more during the taxable year of the disposition and certain other requirements are met; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our common stock constitutes a U.S. real property interest, or USRPI, by reason of our status as a U.S. real property
holding corporation, or USRPHC, for U.S. federal income tax purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Gain described in the first bullet point above generally will be subject to
U.S. federal income tax on a net income basis at the regular rates applicable to U.S. persons. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such
lower rate specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on gain realized upon
the sale or other taxable disposition of our common stock, which may be offset by certain U.S. source capital losses of the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder (even though the individual is not considered a resident of the
United States), provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such losses. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">With respect to the third bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC. Because the determination of whether we are a
USRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> real property interests and our other business assets, there can be no assurance we currently
are not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition of our common stock by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be
subject to U.S. federal income tax if our common stock is &#147;regularly traded,&#148; as defined by applicable Treasury Regulations, on an established securities market, and such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned,
actually and constructively, 5% or less of our common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding
period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable tax treaties that may provide for
different rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Information Reporting and Backup Withholding </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Payments
of dividends on our common stock will not be subject to backup withholding, provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder certifies its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by furnishing a valid IRS
Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> or otherwise establishes an exemption. However,
information returns are required to be filed with the IRS in connection with any distributions on our common stock paid to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, regardless of whether such distributions constitute dividends or
whether any tax was actually withheld. In addition, proceeds of the sale or other taxable disposition of our common stock within the United States or conducted through certain U.S.-related brokers generally will not be subject to backup withholding
or information reporting if the applicable withholding agent receives the certification described above or the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder otherwise establishes an exemption. Proceeds of a disposition of our common stock
conducted through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker that does not have certain enumerated relationships with the United States generally will not be subject to
backup withholding or information reporting. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Copies of information returns that are filed with the IRS may also be made available under the provisions of an
applicable treaty or agreement to the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder resides or is established. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Additional Withholding Tax on Payments Made to Foreign Accounts </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Withholding
taxes may be imposed under Sections 1471 to 1474 of the Code (such Sections commonly referred to as the Foreign Account Tax Compliance Act, or FATCA) on certain types of payments made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial
institutions and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30% withholding tax may be imposed on dividends on, and, subject to the proposed Treasury Regulations discussed below, gross proceeds from the
sale or other disposition of, our common stock paid to a &#147;foreign financial institution&#148; or a <FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (each as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
defined in the Code), unless (1)&nbsp;the foreign financial institution undertakes certain diligence and reporting obligations, (2)&nbsp;the <FONT STYLE="white-space:nowrap">non-financial</FONT>
foreign entity either certifies it does not have any &#147;substantial United States owners&#148; (as defined in the Code) or furnishes identifying information regarding each substantial United States owner, or (3)&nbsp;the foreign financial
institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to the diligence and reporting requirements in
(1)&nbsp;above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain &#147;specified United States persons&#148; or &#147;United States owned
foreign entities&#148; (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to <FONT STYLE="white-space:nowrap">non-compliant</FONT> foreign financial institutions and certain
other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends on our common stock. While
withholding under FATCA would have applied also to payments of gross proceeds from the sale or other disposition of our common stock beginning on January&nbsp;1, 2019, proposed Treasury Regulations eliminate FATCA withholding on payments of gross
proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prospective investors should
consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc432084_10"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are offering the shares of common stock described in this prospectus supplement through a number of underwriters. Jefferies LLC and Cowen and Company, LLC are
acting as joint book-running&nbsp;managers of the offering and as representatives of the underwriters. We intend to enter into an underwriting agreement with the underwriters. Subject to the terms and conditions of the underwriting agreement, we
have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting discounts and commissions set forth on the cover page of this prospectus supplement, the number of
shares of common stock listed next to its name in the following table: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">UBS Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Mizuho Securities USA LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">JMP Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters are committed to purchase all the shares of common stock offered by us if they purchase any shares. The underwriting agreement also provides that if an
underwriter defaults, the purchase commitments <FONT STYLE="white-space:nowrap">of&nbsp;non-defaulting&nbsp;underwriters</FONT> may also be increased or the offering may be terminated. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters propose to offer the shares of common stock directly to the public at the public offering price set forth on the cover page of this prospectus
supplement and to certain dealers at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. After the initial offering of the shares to the public, if all of the shares are
not sold at the public offering price, the underwriters may change the offering price and the other selling terms. Sales of any shares made outside of the United States may be made by affiliates of the underwriters. The offering of the shares by the
underwriters is subject to receipt and acceptance and subject to the underwriters&#146; right to reject any order in whole or in part. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have an
option to buy up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock from us to cover sales of shares by the underwriters which exceed the number of shares specified
in the table above. The underwriters have 30 days from the date of this prospectus supplement to exercise this option to purchase additional shares. If any shares are purchased with this option to purchase additional shares, the underwriters will
purchase shares in approximately the same proportion as shown in the table above. If any additional shares of common stock are purchased, the underwriters will offer the additional shares on the same terms as those on which the shares are being
offered. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriting fee is equal to the public offering price per share of common stock less the amount paid by the underwriters to us per share of common
stock. The underwriting fee is $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters, assuming
both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITHOUT&nbsp;OPTION&nbsp;TO<BR>PURCHASE&nbsp;ADDITIONAL<BR>SHARES EXERCISE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITH&nbsp;FULL&nbsp;OPTION&nbsp;TO<BR>PURCHASE&nbsp;ADDITIONAL<BR>SHARES EXERCISE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate that the total expenses of this offering, including registration, filing and listing fees, printing fees and legal and accounting expenses, but excluding
the underwriting discounts and commissions, will be approximately </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have also agreed to reimburse the underwriters for certain of their expenses in an amount of up to $25,000. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A prospectus supplement in electronic format may be made available on the websites maintained by one or more underwriters, or selling group members, if any,
participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to
underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We<I></I>&nbsp;have agreed that we will not
(i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or
submit to, or file with, the SEC a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exercisable or exchangeable for any shares of our common stock, or publicly disclose the
intention to make any offer, sale, pledge, loan, disposition or filing, or (ii)&nbsp;enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of common stock or
any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the prior written consent of the
representatives for a period of 60 days after the date of this prospectus supplement, other than the shares of our common stock to be sold in this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
restrictions on our actions, as described above, do not apply to certain transactions, including (i)&nbsp;the issuance of shares of common stock or securities convertible into or exercisable for shares of our common stock pursuant to the conversion
or exchange of convertible or exchangeable securities or the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, warrants or options (including net exercise) or the settlement of restricted stock units, or RSUs, (including net
settlement), in each case outstanding on the date of the underwriting agreement and described in this prospectus supplement; (ii)&nbsp;grants of stock options, stock awards, restricted stock, RSUs or other equity awards and the issuance of shares of
our common stock or securities convertible into or exercisable or exchangeable for shares of our common stock (whether upon the exercise of stock options or otherwise) to our employees, officers, directors, advisors or consultants pursuant to the
terms of an equity compensation plan in effect as of the closing of this offering and described in this prospectus supplement, provided that such recipients enter into <FONT STYLE="white-space:nowrap">a&nbsp;lock-up&nbsp;agreement</FONT> with the
underwriters; (iii)&nbsp;the issuance of up to 10% of the outstanding shares of our common stock, or securities convertible into, exercisable for or which are otherwise exchangeable for, our common stock, immediately following the closing of this
offering, in acquisitions or other similar strategic transactions, provided that such recipients enter into <FONT STYLE="white-space:nowrap">a&nbsp;lock-up&nbsp;agreement</FONT> with the underwriters; (iv)&nbsp;our filing of any registration
statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8&nbsp;relating</FONT> to securities granted or to be granted pursuant to any plan in effect on the date of the underwriting agreement and described in this prospectus supplement or any
assumed benefit plan pursuant to an acquisition or similar strategic transaction; or (v)&nbsp;the filing of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> registering certain of our securities after the 30th day
following the date of this prospectus supplement, provided that (i)&nbsp;no sale of any shares of common stock or any securities convertible into or exercisable or exchangeable for common stock shall be made under such registration statement on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> during the <FONT STYLE="white-space:nowrap">60-day</FONT> period following the date of this prospectus supplement and (ii)&nbsp;no prospectus supplement to such registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> shall be filed nor any other filing or public announcement of an intent to sell under such registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> shall be made during the <FONT
STYLE="white-space:nowrap">60-day</FONT> period following the date of this prospectus supplement with respect to the offering or proposed offering of any shares of common stock or any securities convertible into or exercisable or exchangeable for
common stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our directors and executive officers, or the <FONT STYLE="white-space:nowrap">lock-up</FONT> parties, have entered
<FONT STYLE="white-space:nowrap">into&nbsp;lock-up&nbsp;agreements</FONT> with the underwriters prior to the commencement of this offering pursuant to which <FONT STYLE="white-space:nowrap">each&nbsp;lock-up&nbsp;party,</FONT> with limited
exceptions, for a period of 60&nbsp;days after the date of this prospectus supplement, or the restricted period, may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of the representatives,
(1)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any
shares of our common stock or any securities convertible into or exercisable or exchangeable for our common stock (including, without limitation, common stock or such other securities which may be deemed to be beneficially owned by <FONT
STYLE="white-space:nowrap">such&nbsp;lock-up&nbsp;parties</FONT> in accordance with the rules and regulations of the SEC and securities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
which may be issued upon exercise of a stock option or warrant, or collectively with the common stock, <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;securities),</FONT> (2)&nbsp;enter
into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;securities,</FONT> whether any such transaction
described in clause&nbsp;(1) or&nbsp;(2) above is to be settled by delivery <FONT STYLE="white-space:nowrap">of&nbsp;lock-up</FONT> securities, in cash or otherwise, (3)&nbsp;make any demand for, or exercise any right with respect to, the
registration of <FONT STYLE="white-space:nowrap">any&nbsp;lock-up&nbsp;securities,</FONT> or (4)&nbsp;publicly disclose the intention to do any of the foregoing. Such persons or entities have further acknowledged that these undertakings preclude
them from engaging in any hedging or other transactions or arrangements (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative
transaction or instrument, however described or defined) designed or intended, or which could reasonably be expected to lead to or result in, a sale or disposition or transfer (by any person or entity, whether or not a signatory to such agreement)
of any economic consequences of ownership, in whole or in part, directly or indirectly, of <FONT STYLE="white-space:nowrap">any&nbsp;lock-up&nbsp;securities,</FONT> whether any such transaction or arrangement (or instrument provided for thereunder)
would be settled by delivery <FONT STYLE="white-space:nowrap">of&nbsp;lock-up&nbsp;securities,</FONT> in cash or otherwise. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The restrictions described in the
immediately preceding paragraph and contained in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements between the underwriters and the <FONT STYLE="white-space:nowrap">lock-up</FONT> parties do not apply, subject in certain cases to
various conditions, to certain transactions, including (a)&nbsp;transfers of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">as a bona fide gift or gifts, or for bona fide estate planning purposes, </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">by will, other testamentary document or intestacy, </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">to any trust for the direct or indirect benefit of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or any
immediate family member, or if the undersigned is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust, </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">to a partnership, limited liability company or other entity of which the <FONT STYLE="white-space:nowrap">lock-up</FONT>
party and its immediate family members are the legal and beneficial owner of all of the outstanding equity securities or similar interests, </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses
(i)&nbsp;through (iv), </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">if the undersigned is a corporation, partnership, limited liability company, trust or other business entity, (A)&nbsp;to
another corporation, partnership, limited liability company, trust or other business entity that is an affiliate of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, or to any investment fund or other entity controlling, controlled by,
managing or managed by or under common control with the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or its affiliates or (B)&nbsp;as part of a distribution to members partners, shareholders or other equity holders of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party, </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree, separation
agreement or other court order, </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">to us from an employee or other service provider upon death, disability or termination of employment or service, in each
case, of such employee or service provider, </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">as part of a sale of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities acquired (A)&nbsp;in open market
transactions after the completion of this offering or (B)&nbsp;from the underwriters in this offering, </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">to us in connection with the vesting, settlement or exercise of restricted stock units, options, warrants or other
rights to purchase shares of our common stock (including, in each case, by way of &#147;net&#148; or &#147;cashless&#148; exercise), including for the payment of exercise price and tax and remittance payments due as a result of the vesting,
settlement, or exercise of such restricted stock units, options, warrants or rights, provided that any such shares of common stock received upon such exercise, vesting or settlement shall be subject to the terms of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, and provided further that any such restricted stock units, options, warrants or rights are held by the <FONT STYLE="white-space:nowrap">lock-up</FONT> parties pursuant to an agreement or
equity awards granted under a stock incentive plan or other equity award plan, each such agreement or plan which is described in this prospectus supplement (including any exhibits filed herewith), or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(xi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction approved by our
board of directors and made to all shareholders involving a change in control (for purposes hereof, &#147;change of control&#148; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one
transaction or a series of related transactions, to a person or group of affiliated persons, of shares of capital stock if, after such transfer, such person or group of affiliated persons would hold more than 50% of our outstanding voting securities
(or the surviving entity)), provided that if such transaction is not completed, all such <FONT STYLE="white-space:nowrap">lock-up</FONT> securities would remain subject to the restrictions; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">provided that (A)&nbsp;in the case of any transfer, distribution or other disposition pursuant to clause (a)(i),
(ii), (iii), (iv), (v), (vi) and (vii), such transfer shall not involve a disposition for value and each donee, devisee, transferee or distributee shall execute and deliver to the representatives a <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreement, (B)&nbsp;in the case of any transfer, distribution or disposition pursuant to clauses (a)(i), (ii), (iii), (iv), (v), (vi) and (x), no filing by any party (donor, donee, devisee, transferor, transferee, distributer or distributee) under
the Exchange Act or other public announcement shall be required or shall be made voluntarily in connection with such transfer or distribution (other than a filing on a Form 5 made after the expiration of the restricted period referred to above) and
(C)&nbsp;in the case of any transfer or distribution pursuant to clauses (a)(vii) and (viii)&nbsp;it shall be a condition to such transfer that no public filing, report or announcement shall be voluntarily made and if any filing under
Section&nbsp;16(a) of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of common stock in connection with such transfer or distribution shall be legally required during the
restricted period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer; (b)&nbsp;exercise of the options, settlement of RSUs or other equity awards, or the exercise of
warrants granted pursuant to plans described in in this prospectus supplement, provided that any <FONT STYLE="white-space:nowrap">lock-up</FONT> securities received upon such exercise, vesting or settlement shall be subject to restrictions similar
to those in the immediately preceding paragraph; (c)&nbsp;the conversion of outstanding preferred stock, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to acquire common stock, warrants to acquire preferred stock, or convertible
securities into shares of our common stock or warrants to acquire shares of our common stock, provided that any common stock or warrant received upon such conversion shall be subject to restrictions similar to those in the immediately preceding
paragraph; (d)&nbsp;the establishment or amendment by <FONT STYLE="white-space:nowrap">lock-up</FONT> parties of trading plans under Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act, provided that such plan does not provide
for the transfer of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities during the restricted period and no filing by any party under the Exchange Act or other public announcement shall be required or made voluntarily in connection with such
trading plan during the restricted period; and (e)&nbsp;the sale of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities under existing trading plans pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act,
provided that any filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The representatives,
in their sole discretion, may release the securities subject to any of <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;agreements</FONT> with the underwriters described above, in whole or in part at any time. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our common stock is quoted on the Nasdaq Global Select Market under the symbol &#147;TERN.&#148; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with this offering, the underwriters may engage in stabilizing transactions, which involve making bids for, purchasing and selling shares of common stock
in the open market for the purpose of preventing or retarding a decline in the market price of the common stock while this offering is in progress. These stabilizing transactions may include making short sales of common stock, which involve the sale
by the underwriters of a greater number of shares of common stock than they are required to purchase in this offering, and purchasing shares of common stock on the open market to cover positions created by short sales. Short sales may be
&#147;covered&#148; shorts, which are short positions in an amount not greater than the underwriters&#146; option to purchase additional shares referred to above, or may be &#147;naked&#148; shorts, which are short positions in excess of that
amount. The underwriters may close out any covered short position either by exercising their option to purchase additional shares, in whole or in part, or by purchasing shares in the open market. In making this determination, the underwriters will
consider, among other things, the price of shares available for purchase in the open market compared to the price at which the underwriters may purchase shares through the option to purchase additional shares. A naked short position is more likely
to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market that could adversely affect investors who purchase in this offering. To the extent that the underwriters create a
naked short position, they will purchase shares in the open market to cover the position. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that, pursuant to Regulation&nbsp;M of
the Securities Act, they may also engage in other activities that stabilize, maintain or otherwise affect the price of the common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase
common stock in the open market in stabilizing transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These activities may have the effect of raising or maintaining the market price of the common stock or preventing or
retarding a decline in the market price of the common stock, and, as a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may
discontinue them at any time. The underwriters may carry out these transactions on the Nasdaq Global Select Market, in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;over-the-counter&nbsp;market</FONT></FONT> or
otherwise. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, in connection with this offering certain of the underwriters (and selling group members) may engage in passive market making transactions
in our common stock on The Nasdaq Stock Market prior to the pricing and completion of this offering. Passive market making consists of displaying bids on The Nasdaq Stock Market no higher than the bid prices of independent market makers and making
purchases at prices no higher than these independent bids and effected in response to order flow. Net purchases by a passive market maker on each day are generally limited to a specified percentage of the passive market maker&#146;s average daily
trading volume in the common stock during a specified period and must be discontinued when such limit is reached. Passive market making may cause the price of our common stock to be higher than the price that otherwise would exist in the open market
in the absence of these transactions. If passive market making is commenced, it may be discontinued at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Selling Restrictions </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus
supplement in any jurisdiction where action for that purpose is required. The securities offered by this prospectus supplement may not be offered or sold, directly or indirectly, nor may this prospectus supplement or any other offering material or
advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction.
Persons into whose possession this prospectus supplement comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus supplement. This prospectus supplement does not
constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus supplement in any jurisdiction in which such an offer or a solicitation is unlawful. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time to time in the future certain commercial
banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees and commissions. In addition, from time
to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or
loans, and may do so in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>European Economic Area </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In relation
to each Member State of the European Economic Area (each a &#147;Relevant State&#148;), no shares have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation
to the shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus
Regulation, except that offers of shares may be made to the public in that Relevant State at any time under the following exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the Prospectus
Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>provided</I> that no such offer of shares shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or
supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
acknowledged and agreed to and with each of the underwriters and us that it is a &#147;qualified investor&#148; within the meaning of Article 2(e) of the Prospectus Regulation. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the case of any shares being offered to a financial intermediary as that term is used in the Prospectus Regulation, each such financial intermediary will be deemed
to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer
or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in a Relevant State to qualified investors as so defined or in circumstances in which the prior consent of the
underwriters has been obtained to each such proposed offer or resale. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the purposes of this provision, the expression an &#147;offer to the public&#148; in
relation to the shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any
shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>United Kingdom </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No shares have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the
shares which has been approved by the Financial Conduct Authority, except that the shares may be offered to the public in the United Kingdom at any time: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the U.K. Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the U.K.
Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">in any other circumstances falling within Section&nbsp;86 of the Financial Services and Markets Act 2000, as amended
(&#147;FSMA&#148;); </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>provided</I>&nbsp;that no such offer of the shares shall require us or any underwriter to publish a prospectus pursuant to
Section&nbsp;85 of the FSMA or supplement a prospectus pursuant to Article 23 of the U.K. Prospectus Regulation. For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to the shares in the United Kingdom
means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares and the expression &#147;U.K.
Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, in
the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are &#147;qualified investors&#148; (as defined in the U.K. Prospectus Regulation)&nbsp;(i)
who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the &#147;Order,&#148; and/or (ii)&nbsp;who are high net
worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as &#147;relevant persons&#148;) or otherwise in circumstances which
have not resulted and will not result in an offer to the public of the shares in the United Kingdom within the meaning of the FSMA. In the United Kingdom, any investment or investment activity to which this document relates is only available to, and
will be engaged in with, relevant persons. Any person in the UK who is not a relevant person must not act on or rely upon this document or any of its contents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Prospective Investors in Canada </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The shares may be sold only to
purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;45-106&nbsp;Prospectus</FONT> Exemptions or subsection 73.3(1) of the Securities
Act (Ontario), and are permitted clients, as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;31-103&nbsp;Registration</FONT> Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in
accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Securities legislation in certain
provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus supplement (including any amendment thereto) contains a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s
province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to section 3A.3 of National <FONT STYLE="white-space:nowrap">Instrument&nbsp;33-105&nbsp;Underwriting</FONT> Conflicts
<FONT STYLE="white-space:nowrap">(NI&nbsp;33-105),&nbsp;the</FONT> underwriters are not required to comply with the disclosure requirements of <FONT STYLE="white-space:nowrap">NI&nbsp;33-105&nbsp;regarding</FONT> underwriter conflicts of interest in
connection with this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Prospective Investors in Switzerland </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or regulated trading
facility in Switzerland. This document does not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations
or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing
material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither this document nor any
other offering or marketing material relating to the offering, the Company, the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will
not be supervised by, the Swiss Financial Market Supervisory Authority, or FINMA, and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded
to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Prospective Investors in Hong Kong
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to &#147;professional
investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), or the SFO, of Hong Kong and any rules made thereunder; or (b)&nbsp;in other circumstances which do not result in the document being a
&#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong), or the CO, or which do not constitute an offer to the public within the meaning of the CO. No advertisement, invitation
or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed
or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional
investors&#148; as defined in the SFO and any rules made thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Prospective Investors in Singapore </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The representatives have acknowledged that this prospectus supplement and the accompanying prospectus have not been registered as a prospectus with the Monetary
Authority of Singapore. Accordingly, the representatives have represented and agreed that it has not offered or sold any shares or caused the shares to be made the subject of an invitation for subscription or purchase and will not offer or sell any
shares or cause the shares to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus supplement and the accompanying prospectus or any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares, whether directly or indirectly, to any person in Singapore other than: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of
Singapore, as modified or amended from time to time, or the SFA) pursuant to Section&nbsp;274 of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any
person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of
which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary
of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">securities&nbsp;or securities-based derivatives contracts (each term as defined in
Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to
an offer made under Section&nbsp;275 of the SFA except: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in
Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based
Derivatives Contracts) Regulations 2018. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The shares have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none of the shares,
nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any &#147;resident&#148; of Japan (which term as used herein means any person resident in Japan, including any corporation or other
entity organized under the laws of Japan), or to others <FONT STYLE="white-space:nowrap">for&nbsp;re-offering&nbsp;or</FONT> resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption
from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Prospective Investors in the United Arab Emirates </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The shares have
not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the Dubai International Financial Centre) other than in compliance with the laws of the United Arab Emirates (and the Dubai
International Financial Centre) governing the issue, offering and sale of securities. Further, this prospectus supplement does not constitute a public offer of securities in the United Arab Emirates (including the Dubai International Financial
Centre) and is not intended to be a public offer. This prospectus supplement has not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority or the Dubai Financial Services Authority.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Prospective Investors in Israel </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the State of Israel this
prospectus supplement shall not be regarded as an offer to the public to purchase shares of common stock under the Israeli Securities Law, 5728&#151;1968, which requires a prospectus to be published and authorized by the Israel Securities Authority,
if it complies with certain provisions of Section&nbsp;15 of the Israeli Securities Law, 5728&#150;1968, including, inter alia, if: (i)&nbsp;the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions, or
the Addressed Investors, or (ii)&nbsp;the offer is made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law, 5728&#151;1968, subject to certain conditions, or the Qualified Investors.
The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase securities in addition to the 35 Addressed Investors.&nbsp;The company has not and will not take any action that would
require it to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728&#151;1968.&nbsp;We have not and will not distribute this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
prospectus supplement or make, distribute or direct an offer to subscribe for our common stock to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed
Investors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Qualified Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities Law,
5728&#151;1968.&nbsp;In particular, we may request, as a condition to be offered common stock, that Qualified Investors will each represent, warrant and certify to us and/or to anyone acting on our behalf: (i)&nbsp;that it is an investor falling
within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728&#151;1968; (ii) which of the categories listed in the First Addendum to the Israeli Securities Law, 5728&#151;1968 regarding Qualified Investors is
applicable to it; (iii)&nbsp;that it will abide by all provisions set forth in the Israeli Securities Law, 5728&#151;1968 and the regulations promulgated thereunder in connection with the offer to be issued common stock; (iv)&nbsp;that the shares of
common stock that it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728&#151;1968: (a) for its own account; (b)&nbsp;for investment purposes only; and (c)&nbsp;not issued with a view to resale within the State
of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728&#151;1968; and (v)&nbsp;that it is willing to provide further evidence of its Qualified Investor status.&nbsp;Addressed Investors may have to submit written
evidence in respect of their identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&#146;s name, address and passport number or Israeli identification number. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc432084_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The validity of the issuance of the securities offered hereby will be passed upon by our counsel, Latham&nbsp;&amp; Watkins LLP, Menlo Park, California. The
underwriters are being represented in connection with this offering by Davis Polk&nbsp;&amp; Wardwell LLP, New York, New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc432084_12"></A>EXPERTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, as set forth in their report which is incorporated by reference in this prospectus supplement and elsewhere in the registration statement. Our financial statements are
incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc432084_13"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, of which this prospectus forms a
part. The rules and regulations of the SEC allow us to omit from this prospectus supplement and the accompanying prospectus certain information included in the registration statement. For further information about us and the securities we are
offering under this prospectus supplement and the accompanying prospectus, you should refer to the registration statement and the exhibits and schedules filed with the registration statement. With respect to the statements contained in this
prospectus supplement and the accompanying prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects by the complete text of the agreement or document, a copy of which has
been filed as an exhibit to the registration statement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We file reports, proxy statements and other information with the SEC under the Exchange Act. The SEC
maintains an Internet website that contains reports, proxy statements and other information about issuers, like us, that file electronically with the SEC. The address of that website is<I>&nbsp;www.sec.gov</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptoc432084_14"></A>INFORMATION INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The SEC allows us to &#147;incorporate by reference&#148; the information we file with them which means that we can disclose important information to you by referring
you to those documents instead of having to repeat the information in this prospectus supplement and the accompanying prospectus. The information incorporated by reference is considered to be part of this prospectus supplement and the accompanying
prospectus, and later information that we file with the SEC will automatically update and supersede this information. Any statement contained in a previously filed document incorporated by reference will be deemed to be modified or superseded for
purposes of this prospectus to the extent that a statement contained in this prospectus modifies or replaces that statement. We incorporate by reference the documents listed below and any future information filed (rather than furnished) with the SEC
under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act between the date of this prospectus and the termination of this offering, provided, however, that we are not incorporating any information furnished under Item&nbsp;2.02 or Item&nbsp;7.01
of any current report on Form <FONT STYLE="white-space:nowrap">8-K:</FONT> </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1831363/000095017022002962/tern-20211231.htm">Form <FONT
STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2021, filed with the SEC on March&nbsp;7, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the information specifically incorporated by reference into our Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, from our Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1831363/000095017022006722/tern-def14a-2022.htm">Schedule 14A</A>, filed
with the SEC on April&nbsp;29, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2022,
filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1831363/000095017022010118/tern-20220331.htm">May&nbsp;16, 2022</A>, for the quarter ended June&nbsp;
30, 2022, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1831363/000095017022015561/tern-20220630.htm">August&nbsp;8, 2022</A>, and for the quarter ended September&nbsp;
30, 2022, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1831363/000095017022023982/tern-20220930.htm">November&nbsp;9, 2022</A>; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1831363/000095017022000398/tern-20220119.htm">January&nbsp;19,
 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1831363/000095017022004229/tern-20220321.htm">March&nbsp;
21, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1831363/000095017022011812/tern-20220616.htm">June&nbsp;
17, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1831363/000095017022013212/tern-20220726.htm">July&nbsp;
27, 2022</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1831363/000095017022017517/tern-20220811.htm">August&nbsp;16, 2022</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the description of our common stock contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1831363/000119312521014462/d328418d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> filed with the SEC on January&nbsp;22, 2021, including any amendments or reports filed with the SEC for the purposes of updating this description. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These documents may also be accessed on our website at<I>&nbsp;www.ternspharma.com</I>. Except as otherwise specifically incorporated by reference in this prospectus
supplement and the accompanying prospectus, information contained in, or accessible through, our website is not a part of this prospectus supplement and the accompanying prospectus. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will furnish without charge to you, upon written or oral request, a copy of any or all of the documents incorporated by reference, including exhibits to these
documents by writing or telephoning us at the following address: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Terns Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">1065 East Hillsdale Blvd., Suite 100 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Foster City,
California 94404 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(650) <FONT STYLE="white-space:nowrap">275-4254</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Attention: Investor Relations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>$250,000,000 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g432084g04a37.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Terns Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer and sell up to $250,000,000 in the aggregate of the securities identified above from time to time in one or more offerings. This prospectus
provides you with a general description of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each time we offer and sell securities, we will provide a supplement to this prospectus that
contains specific information about the offering and the amounts, prices and terms of the securities. The supplement may also add, update or change information contained in this prospectus with respect to that offering. You should carefully read
this prospectus and the applicable prospectus supplement before you invest in any of our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer and sell the securities described in
this prospectus and any prospectus supplement to or through one or more underwriters, dealers and agents, or directly to purchasers, or through a combination of these methods. If any underwriters, dealers or agents are involved in the sale of any of
the securities, their names and any applicable purchase price, fee, commission or discount arrangement between or among them will be set forth, or will be calculable from the information set forth, in the applicable prospectus supplement. See the
sections of this prospectus entitled &#147;About this Prospectus&#148; and &#147;Plan of Distribution&#148; for more information. No securities may be sold without delivery of this prospectus and the applicable prospectus supplement describing the
method and terms of the offering of such securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE THE &#147;<A HREF="#tx432084_4">RISK
FACTORS</A>&#148; ON PAGE 5 OF THIS PROSPECTUS AND ANY SIMILAR SECTION CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR SECURITIES. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;TERN.&#148; On March&nbsp;7, 2022, the last reported sale price of our
common stock on the Nasdaq Global Select Market was $3.14 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is March&nbsp;14, 2022. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx432084_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx432084_2">WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY
REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx432084_3">ABOUT TERNS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx432084_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx432084_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx432084_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx432084_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx432084_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx432084_9">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx432084_10">GLOBAL SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx432084_11">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx432084_12">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx432084_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx432084_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission, or the SEC, using a &#147;shelf&#148;
registration process. By using a shelf registration statement, we may sell securities from time to time and in one or more offerings up to a total dollar amount of $250,000,000 as described in this prospectus. Each time that we offer and sell
securities, we will provide a prospectus supplement to this prospectus that contains specific information about the securities being offered and sold and the specific terms of that offering. We may also authorize one or more free writing
prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement or free writing prospectus may also add, update or change information contained in this prospectus with respect to that
offering. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or free writing prospectus, you should rely on the prospectus supplement or free writing prospectus, as applicable. Before
purchasing any securities, you should carefully read both this prospectus and the applicable prospectus supplement (and any applicable free writing prospectuses), together with the additional information described under the heading &#147;Where You
Can Find More Information; Incorporation by Reference.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not authorized anyone to provide you with any information or to make any
representations other than those contained in, or incorporated by reference into, this prospectus, any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no
responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We will not make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should
assume that the information appearing in this prospectus and the applicable prospectus supplement to this prospectus is accurate only as of the date on its respective cover, that the information appearing in any applicable free writing prospectus is
accurate only as of the date of that free writing prospectus, and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference, unless we indicate otherwise. Our business, financial
condition, results of operations and prospects may have changed since those dates. This prospectus incorporates by reference, and any prospectus supplement or free writing prospectus may contain and incorporate by reference, market data and industry
statistics and forecasts that are based on independent industry publications and other publicly available information. Although we believe these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have
not independently verified this information. In addition, the market and industry data and forecasts that may be included or incorporated by reference in this prospectus, any prospectus supplement or any applicable free writing prospectus may
involve estimates, assumptions and other risks and uncertainties and are subject to change based on various factors, including those discussed under the heading &#147;Risk Factors&#148; contained in this prospectus, the applicable prospectus
supplement and any applicable free writing prospectus, and under similar headings in other documents that are incorporated by reference into this prospectus. Accordingly, investors should not place undue reliance on this information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When we refer to &#147;Terns,&#148; &#147;we,&#148; &#147;our,&#148; &#147;us&#148; and the &#147;Company&#148; in this prospectus, we mean Terns
Pharmaceuticals, Inc., unless otherwise specified. When we refer to &#147;you,&#148; we mean the potential holders of the applicable series of securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Terns,&#148; &#147;Terns Pharmaceuticals,&#148; the Terns logo and other trademarks, trade names or service marks of Terns Pharmaceuticals, Inc.
appearing in this prospectus are the property of Terns Pharmaceuticals, Inc. All other trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and
trade names in this prospectus may be referred to without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> symbols, but such references should not be construed as any
indicator that their respective owners will not assert their rights thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx432084_2"></A>WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Available Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file reports, proxy
statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information about issuers, such as us, who file electronically with the SEC. The address of that website is
<I>http://www.sec.gov</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our website address is https://<I>www.ternspharma.com</I>. The information on, or accessible through, our website, however, is
not, and should not be deemed to be, a part of this prospectus or any prospectus supplement. We have included our website address as an inactive textual reference only. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and any prospectus supplement are part of a registration statement that we filed with the SEC and do not contain all of the information in the
registration statement. The full registration statement may be obtained from the SEC or us, as provided above. Forms of the indenture and other documents establishing the terms of the offered securities are or may be filed as exhibits to the
registration statement or documents incorporated by reference in the registration statement. Statements in this prospectus or any prospectus supplement about these documents are summaries and each statement is qualified in all respects by reference
to the document to which it refers. You should refer to the actual documents for a more complete description of the relevant matters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Incorporation by
Reference </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC&#146;s rules allow us to &#147;incorporate by reference&#148; information into this prospectus, which means that we can disclose
important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus, and subsequent information that we file with the SEC will
automatically update and supersede that information. Any statement contained in this prospectus or a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a
statement contained in this prospectus or a subsequently filed document incorporated by reference modifies or replaces that statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incorporate by
reference our documents listed below and any future filings made by us with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, which we refer to as the &#147;Exchange Act&#148; in this prospectus,
between the date of this prospectus and the termination of the offering of the securities described in this prospectus. We are not, however, incorporating by reference any documents or portions thereof, whether specifically listed below or filed in
the future, that are not deemed &#147;filed&#148; with the SEC, including any Compensation Committee report and performance graph or any information furnished pursuant to Items 2.02 or 7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> or
related exhibits furnished pursuant to Item 9.01 of Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and any accompanying prospectus
supplement incorporate by reference the documents set forth below that have previously been filed with the SEC: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1831363/000095017022002962/tern-20211231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2021, filed with the SEC on March&nbsp;7, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1831363/000095017022000398/tern-20220119.htm">Form
 <FONT STYLE="white-space:nowrap">8-K</FONT></A> filed with the SEC on January&nbsp;19, 2022; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1831363/000119312521014462/d328418d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> filed with the SEC on January&nbsp;22, 2021, including any amendments or reports filed with the SEC for the purposes of updating this description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All reports and other documents we subsequently file pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this
offering, including all such documents we may file with the SEC after the date of the initial registration statement and prior to the effectiveness of the registration statement, but </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this prospectus from the date of the
filing of such reports and documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may request a free copy of any of the documents incorporated by reference in this prospectus by writing or
telephoning us at the following address: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Terns Pharmaceuticals, Inc., </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1065 East Hillsdale Blvd., Suite 100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Foster City, California 94404 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: +1 (650) <FONT STYLE="white-space:nowrap">525-5535</FONT> Ext.101 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fax: +1 (650) <FONT STYLE="white-space:nowrap">275-4254</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">E-mail:</FONT> <U>investors@ternspharma.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibits to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference in this prospectus or any
accompanying prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx432084_3"></A>ABOUT TERNS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to
address serious diseases, such as NASH and obesity. Our approach is to develop drug candidates based on mechanisms of action that have achieved <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in
clinical trials. Our most advanced drug candidates are under development for the treatment of <FONT STYLE="white-space:nowrap">non-alcoholic</FONT> steatohepatitis, or NASH, using clinically-validated and complementary mechanisms of action to drive
meaningful clinical benefits for patients. In our NASH programs, these mechanisms have demonstrated significant improvements on histological and <FONT STYLE="white-space:nowrap">non-invasive</FONT> markers of the disease, though no drug has been
approved for the treatment of NASH in the United States or Europe. In addition, by developing combination therapies, we are aiming to expand the reach of our single-agent drug candidates through improved response rates, better tolerability and
improved compliance as compared to monotherapy regimens. We also have an oral small-molecule glucagon-like <FONT STYLE="white-space:nowrap">peptide-1</FONT> receptor <FONT STYLE="white-space:nowrap">(GLP-1R)</FONT> agonist in <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> development that may target metabolic diseases such as obesity as well as NASH. Beyond NASH, we plan to explore other indications with high unmet need using our pipeline drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the Cayman Islands on December&nbsp;9, 2016. On December&nbsp;29, 2020, we effected a <FONT
STYLE="white-space:nowrap">de-registration</FONT> under the Cayman Islands Companies Law (2020 Revision) and a domestication under Section&nbsp;388 of the Delaware General Corporation Law (by means of filing a certificate of domestication with the
Secretary of State of Delaware), pursuant to which our jurisdiction of incorporation was changed from the Cayman Islands to the State of Delaware. Our principal executive offices are located at 1065 East Hillsdale Boulevard, Suite 100, Foster City,
California 94404, and our telephone number is (650) <FONT STYLE="white-space:nowrap">525-5535.</FONT><B> </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx432084_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investment in any securities offered pursuant to this prospectus and the applicable prospectus supplement involves risks. You should carefully
consider the risk factors included in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> our most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and any subsequent Quarterly Reports on
Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> we file after the date of this prospectus, and all other information contained or incorporated by reference into this
prospectus, as updated by our subsequent filings under the Exchange Act, and the risk factors and other information contained in the applicable prospectus supplement and any applicable free writing prospectus before acquiring any of such securities.
The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx432084_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from the sale of the securities as set forth in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx432084_6"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following summary describes the capital stock of Terns Pharmaceuticals, Inc. (the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and
&#147;our&#148;) and the material provisions of our amended and restated certificate of incorporation, our amended and restated bylaws, the amended and restated investors&#146; rights agreement to which we and certain of our stockholders are parties
and of the Delaware General Corporation Law. Because the following is only a summary, it does not contain all of the information that may be important to you. For a complete description, you should refer to our amended and restated certificate of
incorporation, amended and restated bylaws and amended and restated investors&#146; rights agreement, copies of which are incorporated by reference as exhibits to the registration statement of which this prospectus is a part. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock
consists of 150,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. As of December&nbsp;31, 2021, there were outstanding: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">25,269,271 shares of our common stock held by approximately 25 stockholders of record; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,577,485&nbsp;shares of our common stock issuable upon exercise of outstanding stock options.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The actual number of stockholders is greater than the number of record holders and includes stockholders who are
beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of our capital stock and provisions of our amended and restated certificate of incorporation and amended and
restated bylaws are summaries of material terms and provisions and are qualified by reference to our amended and restated certificate of incorporation and amended and restated bylaws, copies of which have been filed with the SEC and are incorporated
by reference as exhibits to the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each holder of
common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders
of a majority of the voting shares are able to elect all of the directors. In addition, the affirmative vote of holders of 66 2/3% of the voting power of all of the then outstanding voting stock is required to take certain actions, including
amending certain provisions of our amended and restated certificate of incorporation, including the provisions relating to amending our amended and restated bylaws, the classified board and director liability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to preferences
that may be applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive dividends as may be declared from time to time by our board of directors out of legally available funds. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of our
liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the
satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rights and Preferences </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock have no preemptive, conversion or subscription or other rights, and there are no redemption or sinking fund
provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we
may designate and issue in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fully Paid and Nonassessable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our outstanding shares of common stock are fully paid and nonassessable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors
has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and
privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be
greater than the rights of our common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our
liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain holders of
shares of our common stock, are entitled to certain rights with respect to registration of such shares under the Securities Act of 1933, as amended, (the &#147;Securities Act&#148;). These shares are referred to as registrable securities. The
holders of these registrable securities possess registration rights pursuant to the terms of our amended and restated investors&#146; rights agreement and are described in additional detail below. The registration of shares of our common stock
pursuant to the exercise of the registration rights described below would enable the holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. We will pay the
registration expenses, other than underwriting discounts, selling commissions and stock transfer taxes, of the shares registered pursuant to the demand, piggyback and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registrations described below.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The demand, piggyback and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights described below will terminate upon the
earliest of (i)&nbsp;with respect to each stockholder, such date, on or after the closing of our initial public offering in February 2021, on which all registrable shares held by such stockholder may immediately be sold during any <FONT
STYLE="white-space:nowrap">90-day</FONT> period pursuant to Rule 144 of the Securities Act, or Rule 144, and (ii)&nbsp;the occurrence of a deemed liquidation event, as defined in our amended and restated certificate of incorporation, as currently in
effect. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain holders of shares of our common stock are entitled to certain demand registration rights. Certain investors holding, collectively, 20%
of registrable securities may, on not more than two occasions, request that we register all or a portion of their shares, subject to certain specified exceptions. If any of these holders exercises its demand registration rights, then these holders
will be entitled to register their shares, subject to specified conditions and limitations in the corresponding offering.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration
Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that we propose to register any of our securities under the Securities Act, either for our own account or for
the account of other security holders, certain holders of shares of our common stock will be entitled to certain &#147;piggyback&#148; registration rights allowing them to include their shares in such registration, subject to specified conditions
and limitations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">S-3&nbsp;Registration</FONT> Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain holders of shares of our common stock are entitled to certain Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights.
Certain investors holding at least 10% of registrable securities may, on not more than two registrations on Form <FONT STYLE="white-space:nowrap">S-3</FONT> within any <FONT STYLE="white-space:nowrap">12-month</FONT> period, request that we register
all or a portion of their shares on Form <FONT STYLE="white-space:nowrap">S-3</FONT> if we are qualified to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> subject to specified exceptions. Such request for
registration on Form <FONT STYLE="white-space:nowrap">S-3</FONT> must cover securities with an aggregate offering price which equals or exceeds $1.0&nbsp;million, net of selling expenses. The right to have such shares registered on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> is further subject to other specified conditions and limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Provisions of
Delaware Law and Our Amended and Restated Certificate of Incorporation and our Amended and Restated Bylaws </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of
Delaware law and our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could make the following transactions more difficult: acquisition of us by means of a tender offer; acquisition of us
by means of a proxy contest or otherwise; or removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be
in their best interest or in our best interests, including transactions that might result in a premium over the market price for our shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are
also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or
unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Anti-Takeover Statute </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits persons deemed &#147;interested stockholders&#148; from engaging in a &#147;business combination&#148; with a publicly-held Delaware corporation for three years
following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies.
Generally, an &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#146;s voting
stock. Generally, a &#147;business combination&#148; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with
respect to transactions not approved in advance by the board of directors, such as discouraging takeover attempts that might result in a premium over the market price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Undesignated Preferred Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
ability to authorize undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to effect a change in control of our
company. These and other provisions may have the effect of deterring hostile takeovers or delaying changes in control or management of our company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Special Stockholder Meetings </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
amended and restated certificate of incorporation provides that a special meeting of stockholders may be called at any time by our board of directors but such special meetings may not be called by the stockholders or any other person or persons.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Requirements for Advance Notification of Stockholder Nominations and Proposals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for
election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Elimination of Stockholder Action by Written Consent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation eliminates the right of stockholders to act by written consent without a meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Classified Board; Election and Removal of Directors; Filling Vacancies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is divided into three classes, divided as nearly as equal in number as possible. The directors in each class will serve
for a three-year term, one class being elected each year by our stockholders, with staggered three-year terms. Only one class of directors is elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of
their respective three-year terms. Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the shares of common stock outstanding are able to elect all of our directors. Our amended and restated
certificate of incorporation provides for the removal of any of our directors only for cause and requires a stockholder vote by the holders of at least a 66 2/3% of the voting power of the then outstanding voting stock. Furthermore, any vacancy on
our board of directors, however occurring, including a vacancy resulting from an increase in the size of the board, may only be filled by a resolution of the board of directors unless the board of directors determines that such vacancies shall be
filled by the stockholders. This system of electing and removing directors and filling vacancies may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more
difficult for stockholders to replace a majority of the directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Choice of Forum </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated bylaws provide that, unless we consent in writing to the
selection of an alternative forum, the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: any derivative action or proceeding brought on our
behalf; any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers or stockholders to us or to our stockholders; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law,
our amended and restated certificate of incorporation or our amended and restated bylaws (as either may be amended from time to time); or any action asserting a claim against us that is governed by the internal affairs doctrine. As a result, any
action brought by any of our stockholders with regard to any of these matters will need to be filed in the Court of Chancery of the State of Delaware and cannot be filed in any other jurisdiction; provided that, the exclusive forum provision will
not apply to suits brought to enforce any liability or duty created by the Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;), as amended, or any other claim for which the federal courts have exclusive jurisdiction; and provided further
that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and
restated certificate of incorporation and amended and restated bylaws also provide that the federal district courts of the United States of America are the exclusive forum for the resolution of any complaint asserting a cause of action against us or
any of our directors, officers, employees or agents and arising under the Securities Act. Nothing in our amended and restated certificate of incorporation and amended and restated bylaws preclude stockholders that assert claims under the Exchange
Act from bringing such claims in state or federal court, subject to applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any action the subject matter of which is within
the scope described above is filed in a court other than a court located within the State of Delaware, or a Foreign Action, in the name of any stockholder, such stockholder shall be deemed to have consented to the personal jurisdiction of the state
and federal courts located within the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
State of Delaware in connection with any action brought in any such court to enforce the applicable provisions of our amended and restated certificate of incorporation and amended and restated
bylaws and having service of process made upon such stockholder in any such action by service upon such stockholder&#146;s counsel in the Foreign Action as agent for such stockholder. Although our amended and restated certificate of incorporation
and amended and restated bylaws contain the choice of forum provision described above, it is possible that a court could find that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This choice of forum provision may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for
disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal securities laws
and the rules and regulations thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment of Charter Provisions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amendment of any of the above provisions in our amended and restated certificate of incorporation, except for the provision making it
possible for our board of directors to issue undesignated preferred stock, would require approval by a stockholder vote by the holders of at least a 66 2/3% of the voting power of the then outstanding voting stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of the Delaware General Corporation Law, our amended and restated certificate of incorporation and our amended and restated
bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile
takeover attempts. These provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their
best interests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Select Market Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market under the trading symbol &#147;TERN.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
transfer agent and registrar for our common stock is Computershare, Inc. The transfer agent and registrar&#146;s address is 250 Royall Street, Canton, Massachusetts 02021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation contains provisions that limit the liability of our directors for monetary damages to the
fullest extent permitted by Delaware law. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of
the Delaware General Corporation Law; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of our amended and restated certificate of incorporation and amended and restated bylaws provide that we are required to indemnify our
directors and officers, in each case to the fullest extent permitted by Delaware </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
law. Our amended and restated bylaws also obligate us to advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding, and permit us to
secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under Delaware law. We
have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by our board of directors. With specified exceptions, these agreements provide for indemnification for
related expenses including, among other things, attorneys&#146; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. We believe that these bylaw provisions and indemnification agreements are
necessary to attract and retain qualified persons as directors and officers. We also maintain directors&#146; and officers&#146; liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated
bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action,
if successful, might benefit us and our stockholders. Further, a stockholder&#146;s investment may be adversely affected to the extent that we pay the costs of settlement and damages. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx432084_7"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we include in any applicable prospectus supplement or free writing prospectus, summarizes
certain general terms and provisions of the debt securities that we may offer under this prospectus. When we offer to sell a particular series of debt securities, we will describe the specific terms of the series in a supplement to this prospectus.
We will also indicate in the supplement to what extent the general terms and provisions described in this prospectus apply to a particular series of debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue debt securities either separately, or together with, or upon the conversion or exercise of or in exchange for, other securities described in this
prospectus. Debt securities may be our senior, senior subordinated or subordinated obligations and, unless otherwise specified in a supplement to this prospectus, the debt securities will be our direct, unsecured obligations and may be issued in one
or more series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The debt securities will be issued under an indenture between us and a third party to be identified therein, as trustee. We have
summarized select portions of the indenture below. The summary is not complete. The form of the indenture has been filed as an exhibit to the registration statement and you should read the indenture for provisions that may be important to you. In
the summary below, we have included references to the section numbers of the indenture so that you can easily locate these provisions. Capitalized terms used in the summary and not defined herein have the meanings specified in the indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in this section only, &#147;Terns,&#148; &#147;we,&#148; &#147;our&#148; or &#147;us&#148; refer to Terns Pharmaceuticals, Inc., unless expressly
stated or the context otherwise requires. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of each series of debt securities will be established by or pursuant to a resolution of our board of directors and set forth or determined in the
manner provided in a resolution of our board of directors, in an officer&#146;s certificate or by a supplemental indenture. (Section 2.2) The particular terms of each series of debt securities will be described in a prospectus supplement relating to
such series (including any pricing supplement or term sheet). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We can issue an unlimited amount of debt securities under the indenture that may be in one
or more series with the same or various maturities, at par, at a premium, or at a discount. (Section 2.1) We will set forth in a prospectus supplement (including any pricing supplement or term sheet) relating to any series of debt securities being
offered, the aggregate principal amount and the following terms of the debt securities, if applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and ranking of the debt securities (including the terms of any subordination provisions);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices (expressed as a percentage of the principal amount) at which we will sell the debt
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit on the aggregate principal amount of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates on which the principal of the securities of the series is payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate or rates (which may be fixed or variable) per annum or the method used to determine the rate or rates
(including any commodity, commodity index, stock exchange index or financial index) at which the debt securities will bear interest, the date or dates from which interest will accrue, the date or dates on which interest will commence and be payable
and any regular record date for the interest payable on any interest payment date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where principal of, and interest, if any, on the debt securities will be payable (and the
method of such payment), where the securities of such series may be surrendered for registration of transfer or exchange, and where notices and demands to us in respect of the debt securities may be delivered; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the period or periods within which, the price or prices at which and the terms and conditions upon which we may
redeem the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any obligation we have to redeem or purchase the debt securities pursuant to any sinking fund or analogous
provisions or at the option of a holder of debt securities and the period or periods within which, the price or prices at which and in the terms and conditions upon which securities of the series shall be redeemed or purchased, in whole or in part,
pursuant to such obligation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which and the price or prices at which we will repurchase debt securities at the option of the
holders of debt securities and other detailed terms and provisions of these repurchase obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which the debt securities will be issued, if other than denominations of $1,000 and any
integral multiple thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be issued in the form of certificated debt securities or global debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the portion of principal amount of the debt securities payable upon declaration of acceleration of the maturity
date, if other than the principal amount; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of denomination of the debt securities, which may be United States Dollars or any foreign currency,
and if such currency of denomination is a composite currency, the agency or organization, if any, responsible for overseeing such composite currency; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation of the currency, currencies or currency units in which payment of principal of, premium and
interest on the debt securities will be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if payments of principal of, premium or interest on the debt securities will be made in one or more currencies or
currency units other than that or those in which the debt securities are denominated, the manner in which the exchange rate with respect to these payments will be determined; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the amounts of payment of principal of, premium, if any, or interest on the debt securities
will be determined, if these amounts may be determined by reference to an index based on a currency or currencies or by reference to a commodity, commodity index, stock exchange index or financial index; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions relating to any security provided for the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to, deletion of or change in the Events of Default described in this prospectus or in the indenture
with respect to the debt securities and any change in the acceleration provisions described in this prospectus or in the indenture with respect to the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to, deletion of or change in the covenants described in this prospectus or in the indenture with
respect to the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any depositaries, interest rate calculation agents, exchange rate calculation agents or other agents with respect
to the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions, if any, relating to conversion or exchange of any debt securities of such series, including if
applicable, the conversion or exchange price and period, provisions as to whether conversion or exchange will be mandatory, the events requiring an adjustment of the conversion or exchange price and provisions affecting conversion or exchange;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the debt securities, which may supplement, modify or delete any provision of the indenture as
it applies to that series, including any terms that may be required under applicable law or regulations or advisable in connection with the marketing of the securities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether any of our direct or indirect subsidiaries will guarantee the debt securities of that series, including
the terms of subordination, if any, of such guarantees. (Section 2.2) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue debt securities that provide for an amount less than their stated principal amount to be due
and payable upon declaration of acceleration of their maturity pursuant to the terms of the indenture. We will provide you with information on the federal income tax considerations and other special considerations applicable to any of these debt
securities in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we denominate the purchase price of any of the debt securities in a foreign currency or currencies
or a foreign currency unit or units, or if the principal of and any premium and interest on any series of debt securities is payable in a foreign currency or currencies or a foreign currency unit or units, we will provide you with information on the
restrictions, elections, general tax considerations, specific terms and other information with respect to that issue of debt securities and such foreign currency or currencies or foreign currency unit or units in the applicable prospectus
supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer and Exchange </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each debt
security will be represented by either one or more global securities registered in the name of The Depository Trust Company, or the Depositary, or a nominee of the Depositary (we will refer to any debt security represented by a global debt security
as a &#147;book-entry debt security&#148;), or a certificate issued in definitive registered form (we will refer to any debt security represented by a certificated security as a &#147;certificated debt security&#148;) as set forth in the applicable
prospectus supplement. Except as set forth under the heading &#147;Global Debt Securities and Book-Entry System&#148; below, book-entry debt securities will not be issuable in certificated form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certificated Debt Securities. You may transfer or exchange certificated debt securities at any office we maintain for this purpose in accordance with the
terms of the indenture. (Section 2.4) No service charge will be made for any transfer or exchange of certificated debt securities, but we may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection
with a transfer or exchange. (Section 2.7) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may effect the transfer of certificated debt securities and the right to receive the principal of, premium
and interest on certificated debt securities only by surrendering the certificate representing those certificated debt securities and either reissuance by us or the trustee of the certificate to the new holder or the issuance by us or the trustee of
a new certificate to the new holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Global Debt Securities and Book-Entry System. Each global debt security representing book-entry debt securities will
be deposited with, or on behalf of, the Depositary, and registered in the name of the Depositary or a nominee of the Depositary. Please see &#147;Global Securities.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Covenants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will set forth in the applicable prospectus
supplement any restrictive covenants applicable to any issue of debt securities. (Article IV) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Protection in the Event of a Change of Control
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we state otherwise in the applicable prospectus supplement, the debt securities will not contain any provisions which may afford holders of the
debt securities protection in the event we have a change in control or in the event of a highly leveraged transaction (whether or not such transaction results in a change in control) which could adversely affect holders of debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger and Sale of Assets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not
consolidate with or merge with or into, or convey, transfer or lease all or substantially all of our properties and assets to any person (a &#147;successor person&#148;) unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are the surviving corporation or the successor person (if other than Terns) is a corporation organized and
validly existing under the laws of any U.S. domestic jurisdiction and expressly assumes our obligations on the debt securities and under the indenture; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">immediately after giving effect to the transaction, no Default or Event of Default, shall have occurred and be
continuing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the above, any of our subsidiaries may consolidate with, merge into or transfer all or part of its
properties to us. (Section 5.1) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Event of Default&#148; means with respect to any series of debt securities, any of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of any interest upon any debt security of that series when it becomes due and payable, and
continuance of such default for a period of 30 days (unless the entire amount of the payment is deposited by us with the trustee or with a paying agent prior to the expiration of the <FONT STYLE="white-space:nowrap">30-day</FONT> period);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of principal of any security of that series at its maturity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the performance or breach of any other covenant or warranty by us in the indenture (other than a
covenant or warranty that has been included in the indenture solely for the benefit of a series of debt securities other than that series), which default continues uncured for a period of 60 days after we receive written notice from the trustee or
Terns and the trustee receive written notice from the holders of not less than 25% in principal amount of the outstanding debt securities of that series as provided in the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain voluntary or involuntary events of bankruptcy, insolvency or reorganization of Terns;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other Event of Default provided with respect to debt securities of that series that is described in the
applicable prospectus supplement. (Section 6.1) </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No Event of Default with respect to a particular series of debt securities (except as
to certain events of bankruptcy, insolvency or reorganization) necessarily constitutes an Event of Default with respect to any other series of debt securities. (Section 6.1) The occurrence of certain Events of Default or an acceleration under the
indenture may constitute an event of default under certain indebtedness of ours or our subsidiaries outstanding from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will provide the
trustee written notice of any Default or Event of Default within 30 days of becoming aware of the occurrence of such Default or Event of Default, which notice will describe in reasonable detail the status of such Default or Event of Default and what
action we are taking or propose to take in respect thereof. (Section&nbsp;6.1) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an Event of Default with respect to debt securities of any series at
the time outstanding occurs and is continuing, then the trustee or the holders of not less than 25% in principal amount of the outstanding debt securities of that series may, by a notice in writing to us (and to the trustee if given by the holders),
declare to be due and payable immediately the principal of (or, if the debt securities of that series are discount securities, that portion of the principal amount as may be specified in the terms of that series) and accrued and unpaid interest, if
any, on all debt securities of that series. In the case of an Event of Default resulting from certain events of bankruptcy, insolvency or reorganization, the principal (or such specified amount) of and accrued and unpaid interest, if any, on all
outstanding debt securities will become and be immediately due and payable without any declaration or other act on the part of the trustee or any holder of outstanding debt securities. At any time after a declaration of acceleration with respect to
debt securities of any series has been made, but before a judgment or decree for payment of the money due has been obtained by the trustee, the holders of a majority in principal amount of the outstanding debt securities of that series may rescind
and annul the acceleration if all Events of Default, other than the <FONT STYLE="white-space:nowrap">non-payment</FONT> of accelerated principal and interest, if any, with respect to debt securities of that series, have been cured or waived as
provided in the indenture. (Section 6.2) We refer you to the prospectus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
supplement relating to any series of debt securities that are discount securities for the particular provisions relating to acceleration of a portion of the principal amount of such discount
securities upon the occurrence of an Event of Default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture provides that the trustee may refuse to perform any duty or exercise any of its
rights or powers under the indenture unless the trustee receives indemnity satisfactory to it against any cost, liability or expense which might be incurred by it in performing such duty or exercising such right or power. (Section 7.1(e)) Subject to
certain rights of the trustee, the holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the
trustee or exercising any trust or power conferred on the trustee with respect to the debt securities of that series. (Section 6.12) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No holder of any
debt security of any series will have any right to institute any proceeding, judicial or otherwise, with respect to the indenture or for the appointment of a receiver or trustee, or for any remedy under the indenture, unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that holder has previously given to the trustee written notice of a continuing Event of Default with respect to
debt securities of that series; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of not less than 25% in principal amount of the outstanding debt securities of that series have made
written request, and offered indemnity or security satisfactory to the trustee, to the trustee to institute the proceeding as trustee, and the trustee has not received from the holders of not less than a majority in principal amount of the
outstanding debt securities of that series a direction inconsistent with that request and has failed to institute the proceeding within 60 days. (Section 6.7) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provision in the indenture, the holder of any debt security will have an absolute and unconditional right to receive payment of the
principal of, premium and any interest on that debt security on or after the due dates expressed in that debt security and to institute suit for the enforcement of payment. (Section 6.8) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture requires us, within 120 days after the end of our fiscal year, to furnish to the trustee a statement as to compliance with the indenture.
(Section 4.3) If a Default or Event of Default occurs and is continuing with respect to the securities of any series and if it is known to a responsible officer of the trustee, the trustee shall mail to each Securityholder of the securities of that
series notice of a Default or Event of Default within 90 days after it occurs or, if later, after a responsible officer of the trustee has knowledge of such Default or Event of Default. The indenture provides that the trustee may withhold notice to
the holders of debt securities of any series of any Default or Event of Default (except in payment on any debt securities of that series) with respect to debt securities of that series if the trustee determines in good faith that withholding notice
is in the interest of the holders of those debt securities. (Section 7.5) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification and Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and the trustee may modify, amend or supplement the indenture or the debt securities of any series without the consent of any holder of any debt security:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with covenants in the indenture described above under the heading &#147;Consolidation, Merger and Sale
of Assets&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for uncertificated securities in addition to or in place of certificated securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add guarantees with respect to debt securities of any series or secure debt securities of any series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to surrender any of our rights or powers under the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add covenants or events of default for the benefit of the holders of debt securities of any series;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the applicable procedures of the applicable depositary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the rights of any holder of debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the issuance of and establish the form and terms and conditions of debt securities of any series
as permitted by the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to effect the appointment of a successor trustee with respect to the debt securities of any series and to add to
or change any of the provisions of the indenture to provide for or facilitate administration by more than one trustee; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with requirements of the SEC in order to effect or maintain the qualification of the indenture under
the Trust Indenture Act. (Section 9.1) </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also modify and amend the indenture with the consent of the holders of at least a
majority in principal amount of the outstanding debt securities of each series affected by the modifications or amendments. We may not make any modification or amendment without the consent of the holders of each affected debt security then
outstanding if that amendment will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the amount of debt securities whose holders must consent to an amendment, supplement or waiver;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the rate of or extend the time for payment of interest (including default interest) on any debt security;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal of or premium on or change the fixed maturity of any debt security or reduce the amount of,
or postpone the date fixed for, the payment of any sinking fund or analogous obligation with respect to any series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal amount of discount securities payable upon acceleration of maturity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a default in the payment of the principal of, premium or interest on any debt security (except a rescission
of acceleration of the debt securities of any series by the holders of at least a majority in aggregate principal amount of the then outstanding debt securities of that series and a waiver of the payment default that resulted from such
acceleration); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make the principal of or premium or interest on any debt security payable in currency other than that stated in
the debt security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any change to certain provisions of the indenture relating to, among other things, the right of holders of
debt securities to receive payment of the principal of, premium and interest on those debt securities and to institute suit for the enforcement of any such payment and to waivers or amendments; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a redemption payment with respect to any debt security. (Section 9.3) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of any series may on behalf
of the holders of all debt securities of that series waive our compliance with provisions of the indenture. (Section 9.2) The holders of a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of
all the debt securities of such series waive any past default under the indenture with respect to that series and its consequences, except a default in the payment of the principal of, premium or any interest on any debt security of that series;
provided, however, that the holders of a majority in principal amount of the outstanding debt securities of any series may rescind an acceleration and its consequences, including any related payment default that resulted from the acceleration.
(Section 6.13) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Defeasance of Debt Securities and Certain Covenants in Certain Circumstances </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Legal Defeasance</I>. The indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities, we may be discharged
from any and all obligations in respect of the debt securities of any series (subject to certain exceptions). We will be so discharged upon the irrevocable deposit with the trustee, in trust, of money and/or U.S. government obligations or, in the
case of debt securities denominated in a single currency other than U.S. Dollars, government obligations of the government that issued or caused to be issued such currency, that, through the payment of interest and principal in accordance with their
terms, will provide money or U.S. government obligations in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal, premium and
interest on and any mandatory sinking fund payments in respect of the debt securities of that series on the stated maturity of those payments in accordance with the terms of the indenture and those debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discharge may occur only if, among other things, we have delivered to the trustee an opinion of counsel stating that we have received from, or there has
been published by, the United States Internal Revenue Service a ruling or, since the date of execution of the indenture, there has been a change in the applicable U.S. federal income tax law, in either case to the effect that, and based thereon such
opinion shall confirm that, the holders of the debt securities of that series will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit, defeasance and discharge and will be subject to U.S. federal
income tax on the same amounts, in the same manner and at the same times as would have been the case if the deposit, defeasance and discharge had not occurred. (Section 8.3) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Defeasance of Certain Covenants</I>. The indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities, upon
compliance with certain conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may omit to comply with the covenant described under the heading &#147;Consolidation, Merger and Sale of
Assets&#148; and certain other covenants set forth in the indenture, as well as any additional covenants which may be set forth in the applicable prospectus supplement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any omission to comply with those covenants will not constitute a Default or an Event of Default with respect to
the debt securities of that series (&#147;covenant defeasance&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conditions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">depositing with the trustee money and/or U.S. government obligations or, in the case of debt securities
denominated in a single currency other than U.S. Dollars, government obligations of the government that issued or caused to be issued such currency, that, through the payment of interest and principal in accordance with their terms, will provide
money in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal of, premium and interest on and any mandatory sinking fund payments
in respect of the debt securities of that series on the stated maturity of those payments in accordance with the terms of the indenture and those debt securities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delivering to the trustee an opinion of counsel to the effect that the holders of the debt securities of that
series will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit and related covenant defeasance and will be subject to U.S. federal income tax on the same amounts, in the same manner and at the same
times as would have been the case if the deposit and related covenant defeasance had not occurred. (Section 8.4) </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Personal
Liability of Directors, Officers, Employees or Securityholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of our past, present or future directors, officers, employees or securityholders,
as such, will have any liability for any of our obligations under the debt securities or the indenture or for any claim based on, or in respect or by reason of, such obligations or their creation. By accepting a debt security, each holder waives and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
releases all such liability. This waiver and release is part of the consideration for the issue of the debt securities. However, this waiver and release may not be effective to waive liabilities
under U.S. federal securities laws, and it is the view of the SEC that such a waiver is against public policy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture and the debt securities, including any claim or controversy arising out of or relating to the indenture or the securities, will be governed by
the laws of the State of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture will provide that we, the trustee and the holders of the debt securities (by their acceptance of the
debt securities) irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to the indenture, the debt securities or the transactions contemplated
thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture will provide that any legal suit, action or proceeding arising out of or based upon the indenture or the transactions contemplated
thereby may be instituted in the federal courts of the United States of America located in the City of New York or the courts of the State of New York in each case located in the City of New York, and we, the trustee and the holder of the debt
securities (by their acceptance of the debt securities) irrevocably submit to the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> jurisdiction of such courts in any such suit, action or proceeding. The indenture will further provide that
service of any process, summons, notice or document by mail (to the extent allowed under any applicable statute or rule of court) to such party&#146;s address set forth in the indenture will be effective service of process for any suit, action or
other proceeding brought in any such court. The indenture will further provide that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities) irrevocably and unconditionally waive any objection to the laying
of venue of any suit, action or other proceeding in the courts specified above and irrevocably and unconditionally waive and agree not to plead or claim any such suit, action or other proceeding has been brought in an inconvenient forum. (Section
10.10) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx432084_8"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue warrants for the purchase of shares of our common stock or preferred stock or of debt securities. We may issue warrants independently or together
with other securities, and the warrants may be attached to or separate from any offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between us and the investors or a warrant agent. The
following summary of material provisions of the warrants and warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to a particular series of
warrants. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. We urge you to read the applicable prospectus supplement and any related free writing prospectus, as well as the complete warrant
agreements and warrant certificates that contain the terms of the warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The particular terms of any issue of warrants will be described in the
prospectus supplement relating to the issue. Those terms may include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of common stock or preferred stock purchasable upon the exercise of warrants to purchase
such shares and the price at which such number of shares may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation, stated value and terms (including, without limitation, liquidation, dividend, conversion and
voting rights) of the series of preferred stock purchasable upon exercise of warrants to purchase preferred stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the principal amount of debt securities that may be purchased upon exercise of a debt warrant and the exercise
price for the warrants, which may be payable in cash, securities or other property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on and after which the warrants and the related debt securities, preferred stock or common
stock will be separately transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the warrants will commence and the date on which the right will expire;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. federal income tax consequences applicable to the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any additional terms of the warrants, including terms, procedures, and limitations relating to the exchange,
exercise and settlement of the warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of equity warrants will not be entitled: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to vote, consent or receive dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receive notice as stockholders with respect to any meeting of stockholders for the election of our directors or
any other matter; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exercise any rights as stockholders of Terns. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each warrant will entitle its holder to purchase the principal amount of debt securities or the number of shares of preferred stock or common stock at the
exercise price set forth in, or calculable as set forth in, the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified
time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of warrant certificates may exchange them for new warrant certificates of different denominations, present them for registration of transfer and
exercise them at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement. Until any warrants to purchase debt securities are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercised, the holder of the warrants will not have any rights of holders of the debt securities that can be purchased upon exercise, including any rights to receive payments of principal,
premium or interest on the underlying debt securities or to enforce covenants in the applicable indenture. Until any warrants to purchase common stock or preferred stock are exercised, the holders of the warrants will not have any rights of holders
of the underlying common stock or preferred stock, including any rights to receive dividends or payments upon any liquidation, dissolution or winding up on the common stock or preferred stock, if any. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx432084_9"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue units consisting of any combination of the other types of securities offered under this prospectus in one or more series. We may evidence each
series of units by unit certificates that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or trust company that we select. We will indicate the name and address of the
unit agent in the applicable prospectus supplement relating to a particular series of units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description, together with the additional
information included in any applicable prospectus supplement, summarizes the general features of the units that we may offer under this prospectus. You should read any prospectus supplement and any free writing prospectus that we may authorize to be
provided to you related to the series of units being offered, as well as the complete unit agreements that contain the terms of the units. Specific unit agreements will contain additional important terms and provisions and we will file as an exhibit
to the registration statement of which this prospectus is a part, or will incorporate by reference from another report that we file with the SEC, the form of each unit agreement relating to units offered under this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we offer any units, certain terms of that series of units will be described in the applicable prospectus supplement, including, without limitation, the
following, as applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series of units; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identification and description of the separate constituent securities comprising the units;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which the units will be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on and after which the constituent securities comprising the units will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of certain U.S. federal income tax considerations applicable to the units; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the units and their constituent securities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx432084_10"></A>GLOBAL SECURITIES </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry, Delivery and Form </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we
indicate differently in any applicable prospectus supplement or free writing prospectus, the securities initially will be issued in book-entry form and represented by one or more global notes or global securities, or, collectively, global
securities. The global securities will be deposited with, or on behalf of, The Depository Trust Company, New York, New York, as depositary, or &#147;DTC&#148;, and registered in the name of Cede&nbsp;&amp; Co., the nominee of DTC. Unless and until
it is exchanged for individual certificates evidencing securities under the limited circumstances described below, a global security may not be transferred except as a whole by the depositary to its nominee or by the nominee to the depositary, or by
the depositary or its nominee to a successor depositary or to a nominee of the successor depositary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DTC has advised us that it is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a limited-purpose trust company organized under the New York Banking Law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;banking organization&#148; within the meaning of the New York Banking Law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a member of the Federal Reserve System; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;clearing corporation&#148; within the meaning of the New York Uniform Commercial Code; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;clearing agency&#148; registered pursuant to the provisions of Section&nbsp;17A of the Exchange Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DTC holds securities that its participants deposit with DTC. DTC also facilitates the settlement among its participants
of securities transactions, such as transfers and pledges, in deposited securities through electronic computerized book-entry changes in participants&#146; accounts, thereby eliminating the need for physical movement of securities certificates.
&#147;Direct participants&#148; in DTC include securities brokers and dealers, including underwriters, banks, trust companies, clearing corporations and other organizations. DTC is a wholly-owned subsidiary of The Depository Trust&nbsp;&amp;
Clearing Corporation, or DTCC. DTCC is the holding company for DTC, National Securities Clearing Corporation and Fixed Income Clearing Corporation, all of which are registered clearing agencies. DTCC is owned by the users of its regulated
subsidiaries. Access to the DTC system is also available to others, which we sometimes refer to as indirect participants, that clear through or maintain a custodial relationship with a direct participant, either directly or indirectly. The rules
applicable to DTC and its participants are on file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchases of securities under the DTC system must be made by or through
direct participants, which will receive a credit for the securities on DTC&#146;s records. The ownership interest of the actual purchaser of a security, which we sometimes refer to as a beneficial owner, is in turn recorded on the direct and
indirect participants&#146; records. Beneficial owners of securities will not receive written confirmation from DTC of their purchases. However, beneficial owners are expected to receive written confirmations providing details of their transactions,
as well as periodic statements of their holdings, from the direct or indirect participants through which they purchased securities. Transfers of ownership interests in global securities are to be accomplished by entries made on the books of
participants acting on behalf of beneficial owners. Beneficial owners will not receive certificates representing their ownership interests in the global securities, except under the limited circumstances described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To facilitate subsequent transfers, all global securities deposited by direct participants with DTC will be registered in the name of
DTC&#146;s partnership nominee, Cede&nbsp;&amp; Co., or such other name as may be requested by an authorized representative of DTC. The deposit of securities with DTC and their registration in the name of Cede&nbsp;&amp; Co. or such other nominee
will not change the beneficial ownership of the securities. DTC has no knowledge of the actual beneficial owners of the securities. DTC&#146;s records reflect only the identity of the direct participants to whose accounts the securities are
credited, which may or may not be the beneficial owners. The participants are responsible for keeping account of their holdings on behalf of their customers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">So long as the securities are in book-entry form, you will receive payments and may transfer
securities only through the facilities of the depositary and its direct and indirect participants. We will maintain an office or agency in the location specified in the prospectus supplement for the applicable securities, where notices and demands
in respect of the securities and the indenture may be delivered to us and where certificated securities may be surrendered for payment, registration of transfer or exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conveyance of notices and other communications by DTC to direct participants, by direct participants to indirect participants and by direct
participants and indirect participants to beneficial owners will be governed by arrangements among them, subject to any legal requirements in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Redemption notices will be sent to DTC. If less than all of the securities of a particular series are being redeemed, DTC&#146;s practice is
to determine by lot the amount of the interest of each direct participant in the securities of such series to be redeemed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither DTC
nor Cede&nbsp;&amp; Co. (or such other DTC nominee) will consent or vote with respect to the securities. Under its usual procedures, DTC will mail an omnibus proxy to us as soon as possible after the record date. The omnibus proxy assigns the
consenting or voting rights of Cede&nbsp;&amp; Co. to those direct participants to whose accounts the securities of such series are credited on the record date, identified in a listing attached to the omnibus proxy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">So long as securities are in book-entry form, we will make payments on those securities to the depositary or its nominee, as the registered
owner of such securities, by wire transfer of immediately available funds. If securities are issued in definitive certificated form under the limited circumstances described below and if not otherwise provided in the description of the applicable
securities herein or in the applicable prospectus supplement, we will have the option of making payments by check mailed to the addresses of the persons entitled to payment or by wire transfer to bank accounts in the United States designated in
writing to the applicable trustee or other designated party at least 15 days before the applicable payment date by the persons entitled to payment, unless a shorter period is satisfactory to the applicable trustee or other designated party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Redemption proceeds, distributions and dividend payments on the securities will be made to Cede&nbsp;&amp; Co., or such other nominee as may
be requested by an authorized representative of DTC. DTC&#146;s practice is to credit direct participants&#146; accounts upon DTC&#146;s receipt of funds and corresponding detail information from us on the payment date in accordance with their
respective holdings shown on DTC records. Payments by participants to beneficial owners will be governed by standing instructions and customary practices, as is the case with securities held for the account of customers in bearer form or registered
in &#147;street name.&#148; Those payments will be the responsibility of participants and not of DTC or us, subject to any statutory or regulatory requirements in effect from time to time. Payment of redemption proceeds, distributions and dividend
payments to Cede&nbsp;&amp; Co., or such other nominee as may be requested by an authorized representative of DTC, is our responsibility, disbursement of payments to direct participants is the responsibility of DTC, and disbursement of payments to
the beneficial owners is the responsibility of direct and indirect participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except under the limited circumstances described below,
purchasers of securities will not be entitled to have securities registered in their names and will not receive physical delivery of securities. Accordingly, each beneficial owner must rely on the procedures of DTC and its participants to exercise
any rights under the securities and the indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laws of some jurisdictions may require that some purchasers of securities take
physical delivery of securities in definitive form. Those laws may impair the ability to transfer or pledge beneficial interests in securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DTC may discontinue providing its services as securities depositary with respect to the securities at any time by giving reasonable notice to
us. Under such circumstances, in the event that a successor depositary is not obtained, securities certificates are required to be printed and delivered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As noted above, beneficial owners of a particular series of securities generally will not
receive certificates representing their ownership interests in those securities. However, if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DTC notifies us that it is unwilling or unable to continue as a depositary for the global security or securities
representing such series of securities or if DTC ceases to be a clearing agency registered under the Exchange Act at a time when it is required to be registered and a successor depositary is not appointed within 90 days of the notification to us or
of our becoming aware of DTC&#146;s ceasing to be so registered, as the case may be; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we determine, in our sole discretion, not to have such securities represented by one or more global securities;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an Event of Default has occurred and is continuing with respect to such series of securities,
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">we will prepare and deliver certificates for such securities in exchange for beneficial interests in the global securities. Any
beneficial interest in a global security that is exchangeable under the circumstances described in the preceding sentence will be exchangeable for securities in definitive certificated form registered in the names that the depositary directs. It is
expected that these directions will be based upon directions received by the depositary from its participants with respect to ownership of beneficial interests in the global securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Euroclear and Clearstream </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If so
provided in the applicable prospectus supplement, you may hold interests in a global security through Clearstream Banking S.A., which we refer to as &#147;Clearstream,&#148; or Euroclear Bank S.A./N.V., as operator of the Euroclear System, which we
refer to as &#147;Euroclear,&#148; either directly if you are a participant in Clearstream or Euroclear or indirectly through organizations which are participants in Clearstream or Euroclear. Clearstream and Euroclear will hold interests on behalf
of their respective participants through customers&#146; securities accounts in the names of Clearstream and Euroclear, respectively, on the books of their respective U.S. depositaries, which in turn will hold such interests in customers&#146;
securities accounts in such depositaries&#146; names on DTC&#146;s books. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clearstream and Euroclear are securities clearance systems in
Europe. Clearstream and Euroclear hold securities for their respective participating organizations and facilitate the clearance and settlement of securities transactions between those participants through electronic book-entry changes in their
accounts, thereby eliminating the need for physical movement of certificates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments, deliveries, transfers, exchanges, notices and
other matters relating to beneficial interests in global securities owned through Euroclear or Clearstream must comply with the rules and procedures of those systems. Transactions between participants in Euroclear or Clearstream, on one hand, and
other participants in DTC, on the other hand, are also subject to DTC&#146;s rules and procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors will be able to make and
receive through Euroclear and Clearstream payments, deliveries, transfers and other transactions involving any beneficial interests in global securities held through those systems only on days when those systems are open for business. Those systems
may not be open for business on days when banks, brokers and other institutions are open for business in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cross-market
transfers between participants in DTC, on the one hand, and participants in Euroclear or Clearstream, on the other hand, will be effected through DTC in accordance with the DTC&#146;s rules on behalf of Euroclear or Clearstream, as the case may be,
by their respective U.S. depositaries; however, such cross-market transactions will require delivery of instructions to Euroclear or Clearstream, as the case may be, by the counterparty in such system in accordance with the rules and procedures and
within the established deadlines (European time) of such system. Euroclear or Clearstream, as the case may be, will, if the transaction meets its settlement requirements, deliver instructions to its U.S. depositary to take action to effect final
settlement on its behalf by delivering or receiving interests in the global securities through DTC, and making or receiving payment in accordance with normal procedures for <FONT STYLE="white-space:nowrap">same-day</FONT> fund settlement.
Participants in Euroclear or Clearstream may not deliver instructions directly to their respective U.S. depositaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to time zone differences, the securities accounts of a participant in Euroclear or
Clearstream purchasing an interest in a global security from a direct participant in DTC will be credited, and any such crediting will be reported to the relevant participant in Euroclear or Clearstream, during the securities settlement processing
day (which must be a business day for Euroclear or Clearstream) immediately following the settlement date of DTC. Cash received in Euroclear or Clearstream as a result of sales of interests in a global security by or through a participant in
Euroclear or Clearstream to a direct participant in DTC will be received with value on the settlement date of DTC but will be available in the relevant Euroclear or Clearstream cash account only as of the business day for Euroclear or Clearstream
following DTC&#146;s settlement date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this section of this prospectus concerning DTC, Clearstream, Euroclear and their respective book-entry systems has been
obtained from sources that we believe to be reliable, but we do not take responsibility for this information. This information has been provided solely as a matter of convenience. The rules and procedures of DTC, Clearstream and Euroclear are solely
within the control of those organizations and could change at any time. Neither we nor the trustee nor any agent of ours or of the trustee has any control over those entities and none of us takes any responsibility for their activities. You are
urged to contact DTC, Clearstream and Euroclear or their respective participants directly to discuss those matters. In addition, although we expect that DTC, Clearstream and Euroclear will perform the foregoing procedures, none of them is under any
obligation to perform or continue to perform such procedures and such procedures may be discontinued at any time. Neither we nor any agent of ours will have any responsibility for the performance or nonperformance by DTC, Clearstream and Euroclear
or their respective participants of these or any other rules or procedures governing their respective operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx432084_11"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time pursuant to underwritten public offerings, &#147;at the market&#148; offerings, negotiated transactions, block
trades or a combination of these methods or through underwriters or dealers, through agents and/or directly to one or more purchasers. The securities may be distributed from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each time that we sell securities covered by this prospectus, we will provide a prospectus supplement or supplements that will describe the method of
distribution and set forth the terms and conditions of the offering of such securities, including the offering price of the securities and the proceeds to us, if applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Offers to purchase the securities being offered by this prospectus may be solicited directly. Agents may also be designated to solicit offers to purchase the
securities from time to time. Any agent involved in the offer or sale of our securities will be identified in a prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a dealer is
utilized in the sale of the securities being offered by this prospectus, the securities will be sold to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of
resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an underwriter is utilized in the sale of the securities being offered by this prospectus, an underwriting agreement will be executed with the
underwriter at the time of sale and the name of any underwriter will be provided in the prospectus supplement that the underwriter will use to make resales of the securities to the public. In connection with the sale of the securities, we or the
purchasers of securities for whom the underwriter may act as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter may sell the securities to or through dealers, and those dealers may receive
compensation in the form of discounts, concessions or commissions from the underwriters and/or commissions from the purchasers for which they may act as agent. Unless otherwise indicated in a prospectus supplement, an agent will be acting on a best
efforts basis and a dealer will purchase securities as a principal, and may then resell the securities at varying prices to be determined by the dealer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any compensation paid to underwriters, dealers or agents in connection with the offering of the securities, and any discounts, concessions or commissions
allowed by underwriters to participating dealers will be provided in the applicable prospectus supplement. Underwriters, dealers and agents participating in the distribution of the securities may be deemed to be underwriters within the meaning of
the Securities Act of 1933, as amended, and any discounts and commissions received by them and any profit realized by them on resale of the securities may be deemed to be underwriting discounts and commissions. We may enter into agreements to
indemnify underwriters, dealers and agents against civil liabilities, including liabilities under the Securities Act, or to contribute to payments they may be required to make in respect thereof and to reimburse those persons for certain expenses.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any common stock that we issue and sell will be listed on the Nasdaq Global Select Market, but any other securities may or may not be listed on a
national securities exchange. To facilitate the offering of securities, certain persons participating in the offering may engage in transactions that stabilize, maintain or otherwise affect the price of the securities. This may include
over-allotments or short sales of the securities, which involve the sale by persons participating in the offering of more securities than were sold to them. In these circumstances, these persons would cover such over-allotments or short positions by
making purchases in the open market or by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercising their over-allotment option, if any. In addition, these persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in the open market or by
imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be to
stabilize or maintain the market price of the securities at a level above that which might otherwise prevail in the open market. These transactions may be discontinued at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may engage in at the market offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act. In addition, we may enter
into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement so indicates, in connection with those derivatives, the
third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales
or to close out any related open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and,
if not identified in this prospectus, will be named in the applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise loan or pledge securities to a financial institution or other third party that in turn may
sell the securities short using this prospectus and an applicable prospectus supplement. Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection with a concurrent
offering of other securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The specific terms of any <FONT STYLE="white-space:nowrap">lock-up</FONT> provisions in respect of any given offering will
be described in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters, dealers and agents may engage in transactions with us, or perform services for
us, in the ordinary course of business for which they receive compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx432084_12"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Latham&nbsp;&amp; Watkins LLP will pass upon certain legal matters relating to the issuance and sale of the securities offered hereby on
behalf of Terns Pharmaceuticals, Inc. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx432084_13"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, as set forth in their report which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our
financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>$75,000,000 Shares of Common Stock </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g432084g69a01.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Joint Book-Running
Managers </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Jefferies </B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Cowen </B></P>
<P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Bookrunner </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>UBS Investment Bank </B></P>
<P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I><FONT STYLE="white-space:nowrap">Co-Lead</FONT> Managers </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>Mizuho </B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>JMP Securities </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>A C<SMALL>ITIZENS</SMALL> C<SMALL>OMPANY</SMALL> </B></P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">December&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022 </P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g432084g04a37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g432084g04a37.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[11V4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %%J^4A X0DE-! 0      $X< @   @  ' )0  AR<C,Y,#DX.1P"!0 U
M36EC<F]S;V9T(%=O<F0@+2!0<F]J96-T(%1O=6-A;B M($9O<FT@4RTS(&%N
M9"!!5$TM=C4X0DE-!"4      !#V2[^GGO[\=\PW=,B^-)?G.$))300Z
M  #E    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O
M9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O
M;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R
M;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T
M3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--
M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0   !:.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      -!    !@              T@
M A8    & &< ,  T &$ ,P W     0                         !
M          (6    T@                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG    T@    !29VAT;&]N9P   A8    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   -(
M    4F=H=&QO;F<   (6     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    $.$))300,      G?     0   '\    R   !@
M2P    G# !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
MA  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,
M# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1
M"  R '\# 2(  A$! Q$!_]T !  (_\0!/P   04! 0$! 0$          P !
M @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"
M! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+1
M0P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MQYFFFCTG)?*+[Z6X\S333EJKAPK L%%5UE#F!SU'45.<YN3QP4.9C&$1Y
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M8 ['R^/O'P\]5,CN/\#_ !^?7FS$@G'L5%CJB03F1;)#U]("JY5*@0 Y"'B
MG$X\O84HC][7P[<%); R0 2.O)B% &?BP_KUN0QM(X1<GV7)Q^"B,[$_F7].
M.VO837<$ !3<.$Q_"14Y1 ?8/(0'F'/Q]@^P=&53D,B'/4@C/QZ@GRU\J[KU
M5F'N*DC'U$=OS:?.#]QN2L&V^*GX"Q2[J$(];>L%4=R#EQ"3T6"@ [:K,EU#
MMT79D!.#*01(1TS7$ATU.S%5)2F[OV-8=X6NIH:ZBIHZMHG]1N4<,:5=%4$8
MBDCF4!VC#$>+ S&.5,AAR"LO(.PO25N?8=ZI+C;;E6242S(;C:):B5Z"Y4N?
MMT,M.SF)9FC+""J51-!(0R.%YJWMYXMV3*KF[(\4VR5>GIO6Q^YCWB-BFD'#
MJ/F%"3$. -VSLA4U2L'K-+NS=,$TE$^R;I@0A UB;.MM@N&TK%526"SPJ+9"
MD\4E!2.D<U*IIJGVY(B67QX96$CGDZGF[$DG6=OV[;IMN^MR4<.Y;_4-\L5,
MM/.MSKHY)J:MD%71'PXYPJ-ZM/"OA1J%0@I&O%5&I5X#VR;V,FBQG;/E[)6%
MZ4L**Q7,Q;+0ZNLFU, ' \15O2Z"<60Y3& CJQ+-%""8JZ48^2, CQ7OGT@^
MC*R^-16?;6W=Q7->2,T5HMQML#CH1+6>KD3LI&2E*LR9!1Y8R"-<V>CCT5>F
M+<?J]ROV[]V;2L[<)$2>^7=+M51GV@8+>*Q6IT8$KXE:T#@$2)!.I&KB,7XO
M:XQA2QA;GD>]OCID*]L&1[O-6N3>')RY'3:NETX.** AR!.%B(XIB\@6%8W,
MX]8KW?)KW4&>2@M%N0,2E-9[516V!,]P330I--[^51+,V22"!@#N3MW;D&W*
M1::.YW^[2%566LO][N-WJ92H'4"KG>GIQT "TL$*XZ$,<DL[4+JQ:---&FFC
M331IIHTTT:::---&FFC331IIIVU+[7H[YG7[:YTTTFG?V4X_/*?KCIIK'TTU
MXT_7:_:XIU!6B"A['"/DQ2>P\[&,I>,=IB @)'+!^BX:KEY"/@JD8/'PUO4]
M344DR3TL\U-/&>4<T$KQ2H1V*O&RL#\0=8]524M;!)35E-!5TTH*R05,,<\,
MBD8*O'*K(P.>S CS[@:@S?N&MMFMZBKNN0]@Q=(*B<YC429,E$'4,)A+U5R?
M0G(5JB01\$(=I%%Y !0,4 #ERG8?33OJR!8WKXKO3KC$-UA,S  C.*F%X*G)
MZDEY9,DDD$G.N%=S?8\^C3<9>6.USV&J?),]DG]70MU.31SI4T>,GM'#%T[$
M:KZS]PC[DC#2-II>=XA6$J#)W:'$'8Z<]8/';:";K2CA LI%3$@BJZ6;M3H(
M'/&H(E4. B4A1/SY-MGI[EOE=:K;66-J66KN%#2^+25@DAYU%3%#S,4L*.J@
MOD@2.0!@9R<\/W7[&2#;5LOEVH=R"NAHK3<JOP:ZWF*HX4U)-/X8F@G>)BPC
M[^ @+]3TZ"NH/8'S!^37:,]S]?\ CW:Z4Z<>W_&:N8,QT#'Q2G%G.3S8TV=/
MF!D:]' >2GUBF ! BA8EF[! Q@Z1<&2(/B< &J[UOZ[7VK>KX2!+1T;BD![-
M73E:>C7 ZL#4RQ<P/_;#'L#JZ^CO:S[SWIM[;@#>#7W"/UUE!S';J8-57!P0
M#Q9:*"?PR>AD*+G+#7190=L6,J5=K#E!W%HVG)%DFGTRM:)IL@KZ$[T?DWC:
MM'<CM81E'-"I,FK@G;RQFZ8D6DE$S]D7HU>O2#?[M:*';T4YMU@H*2&E6W4K
MN#6&(9DJ+C49$E7+43%IY$/"F$C<E@##F?2C;GHJVO8K[<MUSTJ7;<]SKZBN
MDNM=#&PH1,Y\*EM-+AH:&&F@$=/'(/$JVC0J]248(K<OU]J&+:5:,BW^=:UF
MDTN%?6*T6!\1PHSAX6-1,X?2#DC1%PY,BW1*90Y4$%E1 !Z$S#R#5*AADJ)8
MX(4,DLKK'&BXRSL<*HR0!D^9( [G7(M140TL$M342+%!"C22R-GBB*,LQP"<
M >X$Z@3_ #OO#8_&SQ[_ (?<_P"&-3'S9OOXNE_7@_>Z@OG=MS\:P?J3_NM?
MJAQ=^&ZY71;(;L,?*KN%4T$4RQ]RZE%53@FF0O.L ',YS%*',0#F/B(:T.VK
MX 2;=+@ DX>$G [X'B]=:C=NW"0!=8,D@#V)QU/Q,6-20W [N]MVU9*K+[@L
ML5[&"5V/*DJQYUO,KEF3P98\\J5MZ(BY'H%D25CS*=OV74#I/L^OD?IP:.VU
MUP,@HJ=Z@Q<?$X,@X<L\<\F7[KBV,9['.I"ON]NM8B-?5)3"8L(N:R'Q. 4O
MQX(WW/-<YQWZ9ZZC5_._<-C\;3'O^'W/^&-9_P V;[^+I?UX/WNH[YW;<_&L
M'ZD_[K4FXO=GMUFL!N]T47E2 >8"8-I%X[R8FWF @T&T3/*5B16,@I&$EA(U
MGDE(U3ICC"*Y!,0#(\E!CVMU:E8+>U.XK"5 @)3D2R>(OM<N'5#RSRQCXZDE
MNUN>@:Z)5(U H8M4A7X )(8F..',\9 4.%[@ZC)_._<-C\;3'O\ A]S_ (8U
M(?-F^_BZ7]>#][J-^=VW/QK!^I/^ZU(3 V]/:GN>D9.'P+G6A9)G(=L+V1@(
M:25;6%NP*<B1Y'T!+MXZ96C4U5$TE)%!BJR3543247(HH0HX-9:[A0*K5E)-
M K'"NR@H3^#S4LH.,G&<].W4:D*"\VNYLR4-=!42(.31HQ$@7\+PW"N5!(!8
M#CDXSD'&5GW>)MFVMOJG&[@,O5K%[R\)R*M52L*4P8LPE$+,&\FJDO'1CYNW
M39*R;$JYWBK8I0<%. BF10Q-*.VU]>LK4=,\ZPX\0H4 4L&*@\V7)8*V,9[?
M$9UK[Q;+6T2W"LCI6G#&(2!SS"%0Y'!&P%++DG'<:D>U=-GK9N]9N$7;-V@B
MZ:NFRI%V[ELX3*J@X063,9-9%9(Y5$E4S&(H0Q3D,)1 =81&"00002"",$$'
M!!![$$8(U(@A@"""",@CJ"#V(/8@CJ".A'4:05)W6;>LC9EO&WNDY1@;#F;&
MS:3=WB@LV\N27KK:&D8R)DU7BSF-0C3E:2$Q&-5.ZOEQ,=VF9,#D YBY<MOK
M8*:&LEIW2FG($4Q*%7+!F7 5BPY*K,"5 ('Q&<""[6ZIK)[?!51R5E,&,].H
M?G&$94<L2H7V6=5(#$Y/;H<?>>-U>W+;#'Q<EGW,5(Q>C.'4)"-K+*@G+3'8
M" .%(N"9INYJ0;MC"4KETSCUFS8QR%753,<H"H[?6U[,M'32U!3',HOLID9'
M-V(12>F 6!.<@8!TK[K;K8J-7UD-*),\!(WMOCOPC4-(P'F54@>9&M5P3OBV
MD;F9M[6<%9\Q_D2S1[4[YS6HJ2696(6*71V[YM!336,E7S%N*A <O&+1PV;"
M<@+JIB8H#N5=IN- H>KHYH$)P'90R9/8<T+(">X!8$^6MJAOEIN4C14-?!42
MJ.1C5BLG$8RP2149@,@$J" 3WU8Q4OM>C_F=?MKG4?J5TFG?V4X_/*?KCIIK
M'TTT:::---+W+GW*<G?H]NG[MR6IW:_TFV[^7;1^T*?5:WG]#]V?T:OO[+JM
M<E!?8'S!_P M>EC=S]9_MUX^:N"X6&+>U=7[,C]#F1L0E#KISEYAVZW<YBPN
M$A$.0'31"':E4((\R.'28_?#75[[(K<7&*R[5A?K(S7FN"G^)'XM+0QM@]G<
MU<A4CO%$VNYWV)FT^<^X=ZU">S"J[>MK,I^^R""NN4BYZ96+U&-6'4K-*N1[
M2ZN7UU7UW:UH^2\<4W,&/[AB[(D.%@HU]@)&KVN#,]D(X)6#E4#-G[(7T4Z8
MR30%T3F)V[)XV<I\^I)8A@ =;L$\M--'40/PFA=9(WP&XNIRIXL"IP<'!!!\
MQK8J::&LIYJ6H3Q()XVBE0EE#HXPRDJ589'3*L#[B#KEXXS7#1V5;5=F+G*N
M!\,I46^$RC1*Z6=)=<A3QBP\P2;-(M.X6:US,8/>!:-Q[868KI]G]:5(!C]5
M]VS>[I<;F*>LJ3-#X$KE#'"GM+QP0T<:G(&1U)'7MGJ.,MX;;LUJLYJJ&C6"
M?UF"+Q!+4.>#\RPXRS2+UXC^+GXZF+L>X17#XR=M*VPY9O& 49N_W3#6-;I9
M9\<A928FDK++5R-E'\D,?'75I%M17?*'7[LS9(,T^?9I($3 "!&77<=YI[C7
M4T-84ABJ9HXT\& \4#D*N6C9C@=,EB?CJ6L>T[!5VBV5=10*]1/1TTTLGCU(
M+2O&K,V%F5!ENH 3B/<?.+/U2LVCW+W8NTE.R"*7MN4V\CVRHH(A'JKXL3>=
MJN"B0HI V,IVBH*D%,G,X'*(<PSMCEA\K%<\@D!7S/+A4$>_)S\#J.](P0FQ
MJ^.!EJP^3@<":0-D^0QG)ST[ZE4&P[@"" <WVV_GR\?]+6>#Q_\ >+6%\J[P
M_!KOSV]#_7ZMJ1^0]A?AVO\ _4D_[W30WJ4#;QC#@V;B*5M75K*V$(F@RIZF
MI3[BXOM?%P_RC'2%B!E:'4U85WYBV)U*%<D/+.09N@69E*@5 $$]BU35L^YZ
M*6X"3UII@)/%C$3^S3,J90*@'L!<>R,C!\\ZR[S3V^EV=7PVLQ&B6$F(PRF>
M/+5:-)QD,DI;[87!]LX((Z8P*Q.&IM*X0F3=EF'+MNC=X33SG,C?_74ENW$2
M]%L !'Y-N477._U9KDFOH1@#564(+7HB6G?&8MWYNW.Z,X5G;Y<-R072IBMX
MJ_5%\'PO#HUF3+01L_&0P/R^V,P;#'#9&>F!6-N6O:-59Z2:Z-0"N<U'C>-<
M'ADPM1*L7*(5,07[4$XG@.2X;KG)C-NUH>U';'Q#-E+SA=V]A*7:1N58);*I
MCF_O<E5EA)O[A!0L/%IV%>:G5C*7B!DK#&VRN+3SILG#)MG"[:/0E#&<9MNG
MN-=9[HM_C981&_AR3PB"0H(F=W$?%01$ZHT<G$<G. ?9U&W:"TVW<%F;:\R/
M,TT(EBIYS41*[2HJ*LID?[]&\BS1F1@$"L0H<ZE+]4LP3^TY.V0UB+!$9.QM
MLG0,=WA3L6_?Y>P8WCVG;K=)NR1[PX3!53I-T$ZC=(\N6H[8Y"PW5VSQ0T[M
M@9/%4J"<#IDX';.I3TD(9*NR1KCE(E7&N>@Y/+2J,GR&2!G4J^!UO=M,E&V/
MAY;D>_U_/6WI28AJ,VL@BC+S-*K+H64K279UU3F=6#'+@#HL"HB8KVDBS.T*
MHWKKQVM@[KM<:LEYH2)*2LXM,4QQ260964  $),".1ZXESGJ^I79%[D99=OW
M'E'74!=8!+@.\,;!7ISD]9*8G"CNT/5<B/)4?#Y_M\.(?_PGEK_].Q'K>O'T
M0L_\JC_N)??K#L'T^W%_(K/^:I=1(O-<P!N"XX&XVH\1^YC7,;U<)>&QC#6V
MVO*+3Y%O#-:R.-JP\LB;R--7H&6I\I*7-$C26A$IRQ+]:D@HZEEF<E)PR5E)
MM6B>R1%YY/#>=XHQ+(I?Q/'D5"&Y.L@6+JK,B9&,*"L5414%?O6XQ;BF\.FC
MYI3K-*T$+A%C]5B:4,ACC:)VF #IXDA'M9=E:;EMX1.W^YYDP]G;A5;@,3XP
ML6(I]M-V^.BLH365H<[Z,D&#N%>LEHV:M\Q&*R#<9:'L<;)R 0LO&+MD$V1!
M/(][BX]Q5D--54FX**IJ$J498RT"4[ ,A5E/)8U89"NG$<E(/M8X@34VTZ">
MKHZ[:M?1T\E&X>55JGJDY*59&4H\SIS]M)5+<'1@N!ABW6;4>KU=C>KEU=+G
MJY<^75WQQSY<_'ESY\N?CR]NJ-KDH=AGOYZ3;O[*<?GE/UQTTUCZ::---&FF
ME[ES[E.3OT>W3]VY+4[M?Z3;=_+MH_:%/JM;S^A^[/Z-7W]EU6N2I,ISBF1,
MHG.<2$(0H")C&.(%*4H!XB81$   \1$0 /$=>E;$ L20 ,DDG  &222>@ '<
MZ\?0"Q"@$DD  #))/8 >9/8#N3T&NJ+;3BXN'<(T"BJ(D1E6,*E(6(2@'4I8
MYHQI69 YP !5[L\='8(G$ 'NS1 @ !2% /.C?^XCNG=U[NZN6II:MH*#.<+0
M4@%/2X!)X^)%&)F4=/$E<]R2?6CT7[5&S-B;=L+HJ5D%"E3<R!U:YUQ-76AF
MP"_@S3&F1CVA@C0>RH >NJ=J_P"C335%OU1!_9WN_P!-F,?_ *[)JV[+_AD?
MS:;^Q=4CT@?1\_SVF_LEU/[AP?U!=G'_ '<<2?N;%:AKW_"]R_GD_P#>'4YM
MKZ/V;\G4O]TNJ-/JE>.;S#_8Q$O!4*TE+;E2.=&2,4BI6[U;%C9<4CF*<I%
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0P\S&$?$1Y<^0>'(---?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g432084g33a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g432084g33a01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[12"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %&:^4B(X0DE-! 0      %D< @   @  ' )0  AR<C$U,3$X,1P"!0!
M36EC<F]S;V9T(%=O<F0@+2!0<F]J96-T($EN=&5R;&%G;W,@+2!0<F5L:6T@
M4')O<W!E8W1U<R!3=7!P;&5M90 X0DE-!"4      !"HU @,\S?*TND=E@$[
M0!<K.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M             #^    X0DE-! T       0   !:.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         !
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      -!    !@
M            T    A4    & &< ,P S &$ ,  Q     0
M           !              (5    T                      !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG    T     !29VAT;&]N9P   A4    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   -      4F=H=&QO;F<   (5     W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    $.$))300,      G@     0
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MP]-UX_-&
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$!_\  $0@ 0P"K P$1  (1 0,1 ?_$ !X    & P$!
M       !!@<("0(%"@,$_\0 91    4" P,&! T*#!<!     0(#! 4&!P (
M$0D2(1,4,4%A\!4B47$6(S1#4V-S@9&AL;/!"A<F,C-4@]'A\1@D-SE"1E)8
M8K72TQD:)R@U.D5'2%9D9G)T=G>$AI.4HJ.RMO_$ !T!  $$ P$!
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M@!:5AJ>#!<%C)(%Q41>S:X9Z8DKUG8O939IY$VZ<&%37-@:N!LF;Q]Q9>E*
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MN6I,J.U%0$"3V"0/+# _5.#9J2CLE+(X 1D2MKL-3%,<0*1L6,MLD8#*B(&
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M>;\3XGM(!L3QXP3V),(^X<>\EZ!KB*CD3.7\G1]2QS%N33?7>/89ZV;(DU$
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MZ\=<)) Y)N8)'CWOXW\>/,R8Q*@B0H$(BD4@$Y,"%3(4H)ZB.X!0#0"<1\4
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LMY/=,!2#R.T=\!L#Z'&X:,FQ&Z12IZ% #:!OJ#TG,(\1.(](C@  L,+C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g432084g39a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g432084g39a01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1@L4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &!"^86 X0DE-! 0      &$< 5H  QLE1QP"   "   < E  "')R,34Q
M,3@Q' (% $!-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@26YT97)L86=O<R M
M(%!R96QI;2!0<F]S<&5C='5S(%-U<'!L96UE #A"24T$)0      $/Y)@SYB
MFSO2A$T$/_Y#'#<X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q <ZI)P         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-
M!"8       X             /X   #A"24T$#0      !    %HX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M T$    &              -H   'P     8 9P S #D 80 P #$    !
M                      $             !\    -H
M      $                         $     $       !N=6QL     @
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M      !,969T;&]N9P          0G1O;6QO;F<   -H     %)G:'1L;VYG
M   'P     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I
M9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4
M>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   #:     !29VAT;&]N9P  !\     #=7)L5$58
M5     $       !N=6QL5$585     $       !-<V=E5$585     $
M  9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (
M8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E
M2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI
M8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    1
M15-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M      IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M       +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M       X0DE-!!$       $! #A"24T$%       !     0X0DE-! P
M#8(    !    GP   $8   '@  "#0   #68 &  !_]C_[0 ,061O8F5?0TT
M O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( $8 GP,!(@ "$0$#$0'_W0 $  K_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M8#O0<W].YV[^;_[3_P"F_F?1KNRMA,7*20
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0'_P  1" $* ET# 1$  A$! Q$!_\0 '@ !  (#  ,! 0
M  <(!08) 0,$ @K_Q !M$   !@(! 0('"08,#0\+!0 " P0%!@<  0@1$A,)
M%!46(3&7%QA!4597EM375&%QD=76&2(R-3E8=X&4H;'P(R0S.'*2D[*TML'1
MX24G-#9"1E)3<W:'E:6F\29$14=B9'1UA(6G*8*WPM+_Q  < 0$  04! 0
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M!II9G=G%[$$XDTL&&ZDZ5VG2\M1-@:D]?80>DT+^OLI<H7(0W:S5["!0Q1B
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MT>6)681NWK*!B%]0)SN>JDV4NNIR;BO6J;-X%:[6J2M/6@G//='#,P#2(OD
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M@RA-!&+ L2QG-R;&%,K);S)/()Z\.GC*Y+XX<0D,:RT@1)-Z+5%]"DP"^?\
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MYQC&,8QC&,9XWO6O3O>M:]&NN]]/3O?36OW][UK7Q[]&,9X", ^UV!A'V1"
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M?VX@BK@H=(V1.(ZA>]LBU80%*O&VGJ"]J$I#FE !*[(RS=(W5,66G<4ZHDL
M L9]CCQRHEU;ITT+JHA)C59E<1^H)XV$LB5(@DM711-(4<:@*]&C"0G#%6-+
M+9*G:V=,60D1E/;@ DL.E L8R/++X,\/+EF2*P[4XVU!/9NW,[(P(Y-)88TN
M3L4T1I2%7'$@E!Q&]G>0#P]610?HQ4U%C-(0'$$'&E#8S0*)\'EQOIF2$6BY
MU]![$O\ +L"V[%.OA^A+.FGICW;-B3"=JAE*PC7#)41M%+3(:PNFU!SHDC:
MI$G5IDR@]+MC)1:N&/%!CLJ9W$S<>ZH:K2L%'($,PGC?#VE))7DB6I1(Y8(;
MD00 Y&KE*88RI*O;MI%[]H0A.RE6/>Q8QFQD\8>/B>+2^$D5#!R8E/X?#Z_F
MD?+9B0MDE@\ 9-1N%Q1U3:WV5##&V+M-;6V[Z)2$AIY?=B\8.V8QFT1>EJGA
M-A6!:\1K^,1RQ[6(C2:QYBT-I2-[FA4.0#:HQY?4E=G2\QF;1^((SS =^%(
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M'$T>$17IVZ5<2W=1-"J\;T4_GJA5/#X>5/DD:),BC<64O41,Y*M3/19PA@2
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M'\5C]UC[+VH^*=G^54_?X]^W!OD=+_QLWY1Q]CK9?#Z/XK'[K'V7M1\4[/\
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MX.<GW6K\B'_-L?PI4^XMOEX?Y3GC]&<2_M>E.O\ I-*_R0;>5_@YR?=:A_\
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M)68=FMT,6,4XAT[1+UT9E$&G59S2PX!(TYI;8L(>V5+*-2:+*PID\C96W:]
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M5_9:_O=>O^?JZ9H&RYY8^YY_X?J.=8T7/$?JX[1ZO4/+^[GG^S+C-7ZWI?\
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M^R1Y?A]WR]8_W^>7AA7ZW&?A*_D,SE^U_GD_ ?/R\_5Y_P!N=JU/_!_ZE_\
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MX)$DTA1"78Y 7!.0(&.W)4E\YF>&2R4U!8,3K24OIR=&@9;#>$J#R$HVY*A
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ME9W>0N[:Q,*!6ZO3LM3M[6W(2AG+%JY48$I.G3E@_3",,,%K6M^@(==1C$$
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MW5V,GK8BTI0KFU+)U)YZ([?>E!7G(C$Y:8SH,H J.T:SLTW':R($+#N4>L2
M>\WF/<YX_L]UEN2ZM$UK2&9+<S6DKR".8AD05V;AE8Q@!P">5![N1[N=&>&A
MU4*:DB:FD69:PUDH.=SHRWK6UZ:1=T:\K!K%25(_[$X>3UK@)4J0G:$)*<G-
M -'O1'8"'&72G@GL\HRI*^1'E[;U*3SQR3P2!W?U9,J"T+1%QP]@%1(P9'\^
M$X!:/VO<%X5AZP1R1R<ZDP#UD_A#\?\ [/\ +_X9H.VY\_\ \W]OWLZSH/5'
MZ_4/Q@#^X^K+?H/]A)?^0+_O=9HDW\]+_3;^\YU&+^:3^B,^O+67,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QG*:!?LMMU?N -?[W]*U9ZOB_G\>,9U
M9QC&,9R>\,%_6[0+]V5F_P 2YSG>/]'S_E=M?^SMC_Q+69\Y?Z37_(C3_P#:
M>K_X7M<X4TW'I]+G*8Q6#.[.R)7B!O9TZ72-8D;XXGA#$>@?W)0[KUB56%"4
MF7-K8<F5IR=+2U82 )SB]&F:']/]16]5KX=?>V=>>S)!M*RZN.I')-;;964F
MJPI7BC>,R,\4TRNC-X;1EBX/:./D+IBGM]E/L==JK->K%9U5M]K-<EC@I+K*
MC0W)FLS2I((E66O T;HHD\4(J,O<<_$XI22P>.,\NT]0B919\?%<93/E?R9-
M*$2>0I$A+@8RN "24ZI&O.0GA5I2S4W85$!,$48+98@Z:OJ6EL[EG7^C;+7W
MJM:.Z];:TGI2/4D=HA8A+%DDB613'(5?F-BH8#D93;=+W]71J[$6==LM?:M2
M4H[6IOQ7HX[D4:2M6G6/MEAF:%TDC#QA9$[BC$JP$4B0JPGB3B1J0J"@Z$,G
M:8W1Q81["$.Q%]CM@T,0P!UUUKM;&'6NNQ:ZYWQ8BH<2(4)X#A@5)]X-SP3Y
M'U'W#[QXUXQRAF0HX8 ED*L&'!'\I2 ?61QR/61FSR:!2B'-\3=9$V";4TV8
MC)'']&C!M0I:"G9Q9?&3R0[V8D$8M:U?=$*.P>)/HI3LL))Y0APZ6UH[&:_!
M3F$SZVRM2V5![4L&"&SV(Q\I L<\?<R<J')3GN5@)U_47];!KK%V!H(]I5:[
M3#D=\E9+-BIXC(/./F:M*%5PK% C@=KH6SJVG+$:ZS3V\[1E8SP%R?F^.LSP
MZE[0;D+@XH7-Q+-8DJ@(#W1N(3-2C:IS(!M"6:802 \TT8PEQ(NHM18W4G3]
M>Y'8VL-66Y9KP$2BI##+!"1:D0E(9G>PGAP,?%*AF*JH',V7IG=5]#'U+8HS
M5M//=BH5;5A3$+DTT-B<-31P'L0QQUI#+/&&B5BB=Y9NT1R2E4J>\TF3'J=E
MA[9NB"##ME@UU_3F:+"+80>C?Z870/H]>9EG1..]U7D\+W,%[C[PY(Y/WLP:
M1R2=W8C/VCENU2W ]\\ \ >Z3P![ISR!&J-+$<6D4&% ",P1I:<T980%]-FF
M"& &PA 7Z.\%O>M ]':WKKKK0R1@A2Z!B0H4LH)8^H $\DGW!ZS[F56.1@65
M6( )) ) " <DGC@!>0.3Y#D D<C-OKZNI-9TJ98;%41)[J_JE*5$:N,\3:P&
M(T"IU5C5N RQDIRTS>B4JSM[T(>BBM[" 6]ZUO'[;;T=+1L[&](5@JHCR+&!
M),1)*D$82($,[/+(B*/+EF YS):;37][L:NMU\8>S;D>.)I7\&%3'$\TADF8
M=J+'#&\C$^852>/+C-/)3'*#NX3$&*CM]K6BTY0SAB"#KVMA  .Q[#KU[_2^
MC6_3K7IS(LZHO<[!%\O-R% )]PDG@'W/7Z_+,8J.[=B*S-Y\*H))]_@ >]Y_
M@S=(W6DMEC%)9(S-03V>)+(VVO*DXTH@13E+'3;0QMZ<DW>CE*M2H+4&&%E
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M@F<H;&L9K+7Z)L6RA:9L)6T 'AW3,C>0 H?0X]4<M5=H2<H ADI4ZM4=W9)
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MV_\ SG]7^&=MZ?\ 7'_1/]_W_P 'X/>]S+PPK];C/PE?R&9R_:_SJ>YR&/\
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MB A+WXLYJ5B;N]!T,CN>X,V(PL0MP=?!6KU%BJ2>- )K3!RZR<R2VYI)U[U
M4]DSR1\<<J%["2P)R;>FL6+1EM1^%,8:R%.QH^(XJL,,+=KDM[>!(WYY]OW=
MR^3+EPJ^Z=HKU^LK^^_T?O[]&O3FL[?UO_7_ /*?I][U^YF8U'D5_I/_ ' '
M^KC^WG+TU[Z!D_#^I_\ [^GXNGQ^G?HZ_!G+MOZF\O\ :;S_ !_W?XYU[I[^
M0GEQ[7^SE>/5Y9>N ^M+^]_/XOY^CX<YAM_^<_J_PSMW3_\ L?T2?[3][GW?
MP?A\CEX85^MQGX2OY#,Y?M/YY3[X/G[_ /)]SW/[/P>Z>U:D@5_,@>2^O_\
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M<8QC&8-_C$:E:0I!*(\QR1"0H"K)1/[2@>$A*H!9A(%)29Q3J22U 2CCB@G
M!HP)9I@-"T$P6MR:MVY1D,M&W9IRLAC:6K/+7D9"0Q0O"Z,4+*I*D\$J#QR!
MD.[KZ&RB6#8TJE^%'$JQ7*\-F-9 K*)%29'4.%=E# !@&8<\$YJ7N-5!\U-;
M?0:+_DO,A]<?4/Q[N?E2]^_S&?6ITO\ <WHODBA\WQ[C50?-36WT&B_Y+Q]<
M?4/Q[N?E2]^_Q]:G2_W-Z+Y(H?-\>XU4'S4UM]!HO^2\?7'U#\>[GY4O?O\
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MU-;?0:+_ )+Q]<?4/Q[N?E2]^_Q]:?2X]73>A'_Z10^;X]QJH/FIK;Z#1?\
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MG,=UX]C7N@VQ E0C<EP^HNTL7"(VJ5"[0NT<:9OM;Z]<P.SX_#QVCGCCD#D
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MO@%'_O'[W'V(M+\:;7_N?S7/.N$T$UO6_.^8>C>M_P#H/X/_ +5@^R)LO/\
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MZN77=A:E.Q=O^EMBWO;?T;_%=9)M^D>.WI7\]V0]W\G^3X,?A?R?+^:[/O\
MO^?.0=;Z'Z(OH'/HWBV>WGO_ )STF7Q_YSVW'C^)Q[G'';[7C)JR-D[&,8QC
M&,8QC/YH>6-VRV#7.75]605%85J6%)[!=VUL>7[S:C3%%XR[F>69#(78"5:I
M+("H6I4:),D3#/5J!F:+WVR@E'?16OE9==JXXU[Y'U]4@$\!5%>+EF/GY<\
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M<:9&H\T+ >D.1L9LM=WU,=T1TEKQQK6:>6>29_#=!<DJB1!X =064!4[69@
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MDTKQ?/'6% W&K":H! K1=Y(BJ9S#)T:DU]#+8.E;&=?)6IL99&F*=#& YR2
M$YI)T.H_BK)L31+-%6BF6%)?;PO-)"J>D*8R G9(68(S,GM>[MY'.(M=2$6:
M"4ZUEZT]^>N]EZX,-J.O!9>5:3B8.9?&A5(S)&BRCN*%@"19^M>3U:6TXU4V
MP?;XZCMJFA7HSG^()BB(]"1+6!L1@E^]K]G,[XYNKZ8UMS642MV>NC\G*V<
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M7Y2?(:H2RQ"^'U8[KGIG?BF!ZD1S*9&90-T<F29Q-W2.*Y0QJ>C%)&5T++<
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M0O</+SR3].3!+=*M<CAU=^2&2U ]9I+2F-(8Y4KV/'5 EA($5O%@D,8+=GK
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MU]Q=Q;FJJJF>(35"B94S:#=9Z:P9A76[$=$JR4R]4UI(\^&1)?$4R1C"(I*
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H-JP2229I.23R3[8^Z<Z7K %UU(* H%:'@   >T'J \ADOY&R=G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g432084g41a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g432084g41a01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1A24&AO=&]S:&]P(#,N,  X0DE-! 0
M    &#:^89@X0DE-! 0      %D< @   @  ' )0  AR<C$U,3$X,1P"!0!
M36EC<F]S;V9T(%=O<F0@+2!0<F]J96-T($EN=&5R;&%G;W,@+2!0<F5L:6T@
M4')O<W!E8W1U<R!3=7!P;&5M90 X0DE-!"4      !"HU @,\S?*TND=E@$[
M0!<K.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M             #^    X0DE-! T       0   !:.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         !
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      -!    !@
M           #;0  !P,    & &< -  Q &$ ,  Q     0
M           !              <#   #;0                     !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   #;0    !29VAT;&]N9P  !P,    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   VT     4F=H=&QO;F<   <#     W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    $.$))300,      VP     0
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MOV>K5_PGL_ZAQ3]<)K<Z_$V@@VL:U\D>W>W<\N]WT_>W_,24[/J_R'?<EZL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( 1H"0 ,!$0 "$0$#$0'_Q  >  $  00# 0$             !P$&" D#
M! 4""O_$ &T0   & 0(# @8'#Q &!0H$!P$" P0%!@< $0@2(1,Q"105%D%1
M%R)456&4TA@R-E)6<76!D9.QM-'3U",D)3,T-5=R<W22E9:AP? W0D-3LK-$
M182BX0H9)F)D=H.UP_$G1X*&8V6%I,+&U?_$ !H! 0$! 0$! 0
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MB[M<1**\1E8<Q=*:52I4EMDU=^'BE,CSL4#2;5@FFH\C#NV":91=J*A1C -
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ME* "GU,([  >T]/?OW>C4]7PKY&Q6( T)W.PGS6=&V!0$5% -]"=(!,VI58
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M>KZOA>XW30?;J'RK O1,%?9!UH)B=S%^.JIYX6CIO-O ^VF/7U?.=^W7;O\
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MRHM63 K1DS;(EW$J+=JV:I(()E$1$")D*4!$1VW'3US%%AAB+>R?'B5>E?\
MV\@N?V+J]W>,2>P"(@'C*?>/>/[1MN(=_3?X=7UW&_L^$^*=,_AR7R?%=;4(
M=)51^LDJ0R:J*RJ"J*J9P$IDU4E&YDU4S%$2G(<HE, B AL.VGKF+MA_"?%3
MI7?V\AI9"XKKA"E(FK()D(4I")IK(D3(0@<I2$(5 "D(4H 4A"@!2% "E
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M)S;[<P$,(EWV';?;?8=M0@BX(ZP1\T((N")M(B5V=111WDC][JW_ ._E-_\
MG3??0^'SHBD31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$
M31$T1-$7PHHFB0RBJA$DR["910Q2$* B  )C&$"@&X@&XB'4=$75\IQWN]E\
M:0^7HH7 7/CO:Z>4H[W>R^-(?G-%,PW[CW4J@24<(@ /V0B(@ !XTAN(CT
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M;XZ<LD6=&#DHR,*5X19(02 1W&MQ1DSN);)(K:<V6!0TX&18C<)$3:X O6D
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M;#0F#76D0! BL 0#"]H2%](!T^ /4.PCW=.GI'IW= #<:1Q-+Q,5)KH8I%S
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MG;>Q))P,1//3(/'D<+MO'K27(FDH",6S?.F[5])N!18LU%DO&ETBJ$$<ACG
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ME][;_I&IZIB^]A_%]DZ%_#FGLI07N22^]H>O;_?_ .?KZ>J8OO8?Q?9.B?\
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M%%SAC_Y'P3HG\.:K[*,'[CD_O2'Y_5]3QMV?$?!.A?PYI[*4%[DDOO2'VO\
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M_..G%A?/HV5%:-1G)8K<K]JBF$>CXHD!QWC&7--9+*C,' $$6B )K]="LX=
M12A$$".8^YUJ=-L^!_WRL/\ ,V?_ #CZY:]@^OW719+:J+"'B(X0F7$7F*I6
M.Y+Q+O%S3"&6\56NOJ^-DL#B1OTG4)*!G8-RFF+=FYKKNM>46KT5DGC*328.
MF?MTA,7JS$R-($SF:X;>S-#YO!7-S,S@3;*0>!*UX8N\$%DV;ATZGQ0<1=CL
M$/6ZYG6$@Y[$$Y(TVPW23S]>'\K>+-D%%>+,R6<R5/CZ?$N8Y@8S<THVF')5
M>Q<IB;H<>(+6-S4F1(&40(K--32::!<^ADD$F!,6WZ]>H ;35>_;?![<5]QQ
MQ3,7W>;X:\I^;^.:KCNJ9<MD/9X3+^!'E,)Y 97W&=IKL6E+V*7F8..@K,ZB
MYB7A$X^Y(/4R2#R(<]F5TK)) <*ET7:[-4@@C>@-*;*]&^(I$ : B!$@@WZY
MOJI$LG@M(2T8TXG&%@B,26K->7<MLK]1,QV6K)O;7#,(SV/R-%YN<&./*-YX
MWFG)NA-$J&:H.I(G8F G:;08QS-(EH#2"),&9TK2V\ZZIT5'2 22(.ND_;;9
M7%Q986SIE+B>85[&%6Q\YKULX-[CBVWWK)<-+NH>NDLN0(]%<:V^CF#TCJQ-
MHXKJ2/6W:C!&52(Q5._;%;&,,8YK6$F:8@(:#L#^JU#3DJ]KB0  3D@SQ.E(
MTY&RQW2\%?GP]VC5)+)M(EJS45\\LJ[8WTI;2R<G6\J81F<55-DYQXR8-J5!
M2U9</6KVSV!!:8F;>4%G*S]LL'8J:&,T ^R9(;:(]DR:TH=!87J5DX3M(IFW
MDYOG'$@]R]VV^#/SE8)RJY1\X,>.+Y6VU?C#TAI=<BTVG/6I^'2DX5L4@:UU
M1@TLA7;"9IQ)F):#'G:2D!(/(:0%HNJ5PE1C- (@Q)(.4$UQ,PH2-)%(G8*]
M&Z9H"0)$D3#8BFYK.DW4ETWP:MKIM'EJ@SL&.SJ+W+A'L$6_1C)HGBD?P_14
M<SLK4IY TK*)FDG"3\:Z164>F2;+@5\Y(914H8.-)!,FCP1,?JM2T"\;\TZ(
M@$#<:W@DFLCJY1 "LUAX/#B3CI? \K!73&%(L>,X*ATF;R'3I>YLYEY4<>Y+
MD[.9E-U%S'+U#)4;;JJ],P;1%C9Q3R@V!V]D82=>IB0!=(R'2"9),$ BH X1
M!'V-U>C<"(.@$ZT)F>PQ06K>5NZ#?8-QW';J/=N/KVUP79-$31$T16!E'Z!)
M_P#D&_XZVT4-CU>=OF%A=HJNF>2B4SBFK-0*2H (F16G8=%<G+N!N=!5Z14@
ME$! Q3D Q1 0, ;#J<(.UC'.(4D6\^:KU6>WCC$0$IBF=,S%.0Q3D.0RZ0E.
M0Y!$AR& 0$IBF$I@$! 1 =55;!2?.%_BE_ &B+ZT1-$4/9M^A!'[+LOP*Z*'
MZCYA8G'$X$.*1T"+=F?L#.1 K<%Q(;L.V$PE 4NUY.T+N F+N4O40U#3JL8F
M1U  R:_)5:.<7,[H7*6+O$XSBV1XU"9F2-Q"S]RE;$IPZ.L6$L4P-Q\6!V[/
MBYS27=2&+2QO'T]JG:&TB,>+@P.$I 1]3H#7?]LX1;#,L9PXBDS[8.:9X3U#
M@"9 ]LN!]HDB(!T(D1N9'=*WSUCE\Z('EWY?+3'EW[^7QDFW]VW_ (:\HZHY
M?1=SX7Z_,<5GCJHFB*'+Q,JPF0Z*Z2AI::,>%MB0MXA CA=(-HHW:JD.HF )
M"( 0# 81YS%#;81$'GSYA34]0^OGL7@W.S.)]HS17K-@@BMW)E2+3#9)!%P)
MDQ**20IK*F%4H!S"42@'+N(".O;Z#!=B C^4=QW\_-=\$ DR :4ZU'NW?MWB
M._IVZ^K;OWZ>GX?:B'3Z7'C/TFDSO7F(IZ(GKD:4KJ(%9I6=C0B@1$-P >OX
M!ZCL "([[]VP=WH#OT),?7CU?O4B]8A)J :]410FQF9CLYI]T!$>H!N.VX^G
MKTWZ#OMZ!]'34V%C)M6A)O6DW!.Q'!.%B;Q)B3.]"=XBAT3OV 1ZB @/KWZ;
M^D V#H/P@'3??5-:;S&\CAJ/-0536*W!&QXQ6P[:"YE4$-M]OK@'KZ;=0^$?
M@[^@<O3>$1\^NP((%YZC<BA@J$1,1U5K(U I6(M6P@U50V[]_2.P=X;^L0[Q
M'O'??<0VVVZ!H*U.Y('&N]9F? 60:&=XN9H;ZDBNQBE+!]H>X.G4!#T!N(!N
M&P;^D=PT.UZ3K-Z5%=]S>^MX"8BUM=P*0.)D=DU P ;<2@<H;")=Q #!ON.X
M@']X#TZB'7?9,3>@FD;F3M.\[4F2H3>*C+H8F9DVB?O%9 _,MQCY)\(1@/(/
M'[*UGP@%M?5;ARPGBW-])HIL-8N3 I<ZWN7K$?3PE'#51T*5#:M$!AY-X=0\
MVX[,LB1NF"IQ\&*_$8[$_P P4-!E;,.S5%!0!ID2;B>&'2"3FI$Q D$"9-.L
MQ'$J!;MQE>$&K>!\*+Q.>^*R:O60\WY89V<D;ASAJL.<F^.\=X:8791*JTRK
M3TU3'\"T=ED)N0=R4HQL!62+SQ=NN1)%-2.?B!C3F=5[I]ED@!L@0+BI,F"+
M76'.> #)%M&F!6+4[YN#J%=-X\)[QPX?QICF^W6V0]PK,[X/&4R'D&V4V+JL
MLM2,FW^^VJI8$S8];PJ3YB=X#]A6*YD>#9K.:]"RLL[(HT*=L<Q1Q\0!OM4.
M'[5!<F >JHF) WU3,1%;-K6MZ&!PD4)%5GOQ%<:.8+WA*E4?A8M\^QSUC5KC
M*Z<5T^Z"K8K<-<>J8D=7JV$QC<,O03C'=OL4\_3;@1I664XHR3%8ID&C?G<(
M],3&<![) @L+Z5(BLR*R8WO-(@[+HK,5!/ 6%3^HZFM*DA17A'CQXD\N<0./
ME\8W]&VT_)MLL6#\?X,R?!0< X42A.$ZN9RJ><;_ "T(P2LT?+V"YS"L=:%8
MU$E5/#%%M#,4G'9*:@Q79I#C'Z0'"HADYK2#)L!M " F0:3:*U(BIK4F9TJ)
MNIRK7&#Q)UOP2.:^*"X2\!=^)+'LUG2KDF8J(;,:LC/5C-LEC&,?QD68B2)(
M&K-3 ^8C*<PBPC4EIE50?&5#=.E>W!+KN.82* >TYMXO(%]9LDG)I(J"/_)P
MB9^IN=I7KT?C0S?C3@(K>4[%&H9ISXUXG8_AAEFF0['6(F/=VNS9="@,EWUR
MQM'*UF9BH-"18*(3\#%(DDFJ1BK,TGJ2I1@Q2W"#HE^;+4@7=I$1U"(K!5!
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M=652X.J1CR3M;AU2J@XLRRBRLH:)B#)&()EE@9(N$XXJR@-0./F>0YY+3(@
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M*\R9B&'+FECH+LQ@7F1%($Z6M3KTK2"*"-[7@7C7Z0M@&!_WRL/\S9_\X_\
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ME%HT6?NY6,:,&R*KER^=Q+1LS;-D"&46<.'2QB((((ID.=5950J:9"F,8P
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M0JK)H5-,";FY@$P\P 7E !YM?K/X4_\ R/3/_89;CB":4^?)?G?XC_['H_\
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M=&E22:IB502E_(8OX?B8;/0RWT4@AOI'2AGH^'C>T7-#<V&\M;4 @.FDF)@
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MWVW62RRDY=K.Y9BSCRLE).T/I-4&23-%NT3$C=N!DTP.;B\N+CF;E(  'N@
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M9C6)^4<TV,B;:NM.NFD846+IP0!D$%#3<*D4[^(2.N!M>C",,<<P:,[9W.I
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M8G_%!_#F')GTK$,Z96CZ*GS*L;]6#_\ JMM^DZ?FO$_HL+_=?X)^7,/^I?\
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MIQ+1^D>?!2CC+$C;&BLTX;S3F6&60;)&(NU3; B#453 8O9JJ<PG[380$ V
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M@/LD$28F"5YJ',Z@>'?H,F1N8( Z]C%#*_0LU#E>LB\IB<KIB'9G$#'2V51
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M0KDK(G6\KP*$<@LR3,DX6+KKAN:&N:<3HG9LV:"0YH!&6@D1,W@F)%ER>"7
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M,_4::?4*R]PV+U -BDVZ]?G@](<H>@F_*(!T+R<GZB*/T//GJ75<B2@)J%4
M=Q(<3EY3"!MR'((;"'+L;< Y=BE,'M>42CV9"0B00=00GD+1UQ*>"9O6;,3N
MZ#$90Q.XD5>.K+?%\@TR73K1,T5]"90BUXY"B6"+KLO$S3I]# [,X-(QLI'M
MG2Z:'( )'$I?*[!<6R()S-(-S F-;&1(-1L%DMF;5(-9TZO-^$6-9/ DL\J0
MD0_R[;<2#D?'W#C1L485?8[J%GCJ%C3(5"R=/WV-LY*Q8IF6/9*3/1\HVKMI
MK%F4F#/T#2)T#M>W;BB. YP::-+6Z"E"3!$UD$36342%<MIB0 1$P.RFXUN
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MWKNKNF.%K",\M:EY2G).5;HIBY6QB+YZ4'Y\-&;&QYS%*N $""%HWV*0 *Z
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M@!1.8Q@*)A'E#J!"[ !C_.E$Q1,(%W$.C,-V(2&B8$E: )LO&\]Z[O\ NM0
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M[8PA(-)]8L>)W2MKW6A1\RZOT=%-'3EE'S:#&,5?HM2+OVJ78)MSAKI7%T4
M+9!D3.60,M75[NQ)@P1I-[]@K:M.I8?R7A1>,J+I,C*L6N&;&TQNQSOF5YED
M]#LL%3N)3 V#[;C2C.$L9PCB84<U12?L]XGH^+NRSJ48/6M2CY-LR50E2B&!
MBNBXH'F]\N6S9DWJV:;[T&1IXC3Y5L9F5N&X3L^V#.*6?8BV,6;2R84SY9,9
ME58-#,6TA4WE?J]]Q_(*(BLN!I+S3M\<PEU4C@1618*K))I$40(7MAO+ID
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M[.\Q[PQ_QIQ]SYS_ ,/AU4@^\>[P3V=YGWAC_C2_R-$@[GN\$]G:8]X8\/\
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M(G*;Z0_] _R=$3E-](?^@;\FB)RF^D/_ $#?DT1.4WTA_P"@;\FB)RF^D/\
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ME\C1(&PY!/$F?N1M]X2^1HD#8<@GB3/W(V^\)?(T2!L.03Q)G[D;?>$OD:)
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M*NVBQMN9Q6ECFEKI=,DG4&6\-YI))XRM##<"#F$!TY1$1%=)%10 Q%%+U?\
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M)HB:(FB)HB:(FB)HB:(FB)HB:(FB+P+%68FT,B,I5%0P(K%<LW;9=5H_CW9
M$".V#Q Q%VRY0,)1$AN50@F35(HF8Q!)YZU:)J#/%'E;Y,N2:(  $(MY(<J
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MKSXT,J6PK@9=1KCILS<+, 1CDV\S)3"K4XI*RS=TY$R#&(>F 58U$R)GXH"
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M,&#P*^(*Z4VV*/6M;L]>L*K B)Y!"(EF$D=HFX6<MT#.TVJZPHD679NT4Q5
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MG.KNA.<"-\O<TO8X$$9JB ",KIDD5(,FM/DJP'(X$&<M"22#() VH:P)N-U
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M3F/6C;*)++8H=6[NX=Q//XN;@*TOXM$24;$+M6TBFG2[#F&Y9@P20 !((!I
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M#2,</C5]G,OZE S3S()GC1](,1<J%MJA7JSY8A#JCD.PI .7+4D#_P Y@S%
M(BP(3*\[@B&SN(K0GGP 4;7W$O$?,47(S1MC+BBD\#SM.O4)C/$Q[I-K9/89
MCF,81T1YRV11[8#2Q\>/[2,XFP8SLJ]A&\DN[ESQY8^0:%&AS*2Y@=()=E$9
M<Q,  ?J I46BH%X6NU#LL0 2;F*FII-]]!=;]L;QSV(QY1(F3;F:2,93JTP?
MM3<O,V>M(9DW=-S<FY>9%=,Z9N7VO,4=NFO*ZYZS\UZ6_I$B# H5>FHJFB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(OA0A%$U$U"E.0Y#$.0Y
M0,0Y#%$IBF*8! Q3 (@8H@(" B AL.B+HQ$='Q$8QC(I@SC(UDW309Q\>U09
M,FB! ]JBV:-B)(()%W'E323(0NX[ &E[I:R]'1$T1-$31$T1-$31$T1-$31$
MT1-$31$T1-$31$T1-$00 0$!#<!Z" ]PAZAT1>/%P\1&Q!(B.BXZ/BBIN4RQ
MC)BV:QY2.5%5'! 9())M@(X.JJ=<H);*G44,H!A.81LG<J0-@NQ$Q["*C&,;
M%LFD;',6R39DP8-D6;)FW2*!4F[5JW(F@W13* %3223(F0H !2@&H234F3N4
,;8=07H:*IHB:(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g432084g69a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g432084g69a01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1?&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %ZJ^8%@X0DE-! 0      %D< @   @  ' )0  AR<C$U,3$X,1P"!0!
M36EC<F]S;V9T(%=O<F0@+2!0<F]J96-T($EN=&5R;&%G;W,@+2!0<F5L:6T@
M4')O<W!E8W1U<R!3=7!P;&5M90 X0DE-!"4      !"HU @,\S?*TND=E@$[
M0!<K.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M             #^    X0DE-! T       0   !:.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         !
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      -!    !@
M           !-P   R0    & &< -@ Y &$ ,  Q     0
M           !              ,D   !-P                     !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   !-P    !29VAT;&]N9P   R0    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   3<     4F=H=&QO;F<   ,D     W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    $.$))300,      TC     0
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MT[/4#($P71'92V,_='W!'_1\?P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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ME\1ZM-51<X$C5J;1-$JM(J@20D2ZR5I*1*4IN;P*@4\]BYE,7/)6O"0:5+<
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M]]^"VMK6AGD]92<5M-4:G'6Y@<)+S= /W \8PD"/45YTIT%3B4HJ1#M=@U3
M>0@C&RQ>_"/I_P"*M$\.DUQ(U^C2R3-FJ$K4$)L',\)Y*A@''CI$Q?,ZZAH\
MS<=?19X)XC5-K>&EJX5U%?,H2)"3/TB8LDD/2J5XM+<_P>9X*0!RTS6B'R\>
MC1I 6!5<JW*MM*GIQMK]_E'IN*HHLR6>0+NI%DW!U#$'H)/,HQ01R I#Y@&/
M3'"WI@X/XG3+E2M011UBPQHJXBFJ.:UDHF+*)H?^(F36&[F/'G&OH%](/!:I
MLZITI>H:?+4_UCICU=*$"_,M4N6)D@?TF7(+L&)*7X0SD&,@F"S)V@Y(.L!2
M4*;5UY /W]F+0E5$F>D*E3!,!_%4"0]P#<$$!B=@+=XIJ;(G2%E,Z6N4L#[,
MQ!3V>X((=[@W-X^S'[ ALL&<L;WOBY&;WM:_3\MSN7;L&QT&UK7O;J8BUW(*
M6^';Y@V8O8!@PDO9@0I_CW^1%W#7)<N<!%R)'\K/E2.4Z;-5DT*)1 0S23<"
M<P9"(9"J*H ([0* @&6.E3S4SI]4!<RBF7DW8*?XJ*A;)2#'=J:<R*>B*ARF
M<)D[R<A*<Y'*$GHQZQG\=[?S<;-FYMT;?=3;VZ!Q\.KXMGKBVP=K089<]K%F
MW)R?(;6R,Q.&'>X=]@,#S.]\'$/?T5)%:LJ!TB+'S"IW-.S=JIRXD,V5,8Y(
MNM*!48R4?(-,QXK3NQN4[1^=/(SI!%NBIFF7BFI[TE2$Z3K7 W&%*A,NOH^)
M:+0ZI:0QJ=)UI,^GGT\QOMB5,*9LD$D2UJ6I(!+Q?/HAJ5ZYP]Z3. :U:IFE
MZAP?J/$U&A1!%)KW#:J>KI:J2%?N/C24F14K2QG(1+EK=(+LB-D!A#(1^%Q0
M*&8B(AJ    $1$1#( RVCEBWG9',3D.Y P^68#!QT)+B[T/D@>0L^3@9)>UB
M-P 06$/8L'H 7ROJ#.:ETC6IM\Z!)7WPU"S6&>E6BA0.56GJ?.+=RX35(8HI
M/7JT<R.4X*H.77$%(U)<>^F[AKA;QJ*@FC7-70%)-+0S4>KTZPX(JZT"9+E*
M21[4J2F?/!9*TRP0H>BO1E]'/C'C@2-2U.0>&M 6I"TUFIR9@K*N20%!=!II
M$N=.2M*AR3ZE5-3%)*T+G-RQ-78+0AT?M'L&\C2])(U#6J9"@YK^L02GJH45
M$H<=1BJX2!E!$..8<2$9L3*)Y$<JN3 )Q\@\5^DCBGBZ9,]?K52*):B4Z=1E
M<FC <MXI*U3*DCK4S)@<^R$[^]>!O1%P3P#*E'2=,35:DA "]8U$(J:Y2K\R
MI'L)D40.&HY4E2A:8N80Y=T/1T &^6H0]?>QH+W+NYOBX.^7-KW?X%VLZ%Q)
MM=NXS@FPSO<,V(0#OTX@/@,#8="#T/S\V?-B@WWZ]PQ('4=6+ #\SOL#YXM"
M$#P=60= AT;@'V/-SY[APU_AAQFPR4+N/W8-[BQ #9+V)>X=PV/,6A!@#DD/
MAQ[V]V&;9W#"T(3?/[0U=>^K ]&)N^Y-S^#;# Y-\]1"%ZM_TX8R'&#<[%G]
MUNOY1"$R\'5LZ/M#S=6!)+_$V[!OBP-K6)N(0N(#['<FUF[]MP1CX@P@W'O9
M;_;T8G[38!;)# XQW8MN.@#P@\V(.S-U:UF>QW[]^\(39ET]_/J'JW\. O=F
MZ-UQOD9L+7 ):X0N)N]_<< >_IAF+^1+0@V;B.^_2.(>Y(+MU89+EF-[_![8
M!A!OOOXL3AFN.E[GJ1T^S8['K"$V^//7OX>G+4/5@S>\' ?./*W0#!8;PC>-
M?4'C'[,3;\57_"G]$(TYU\9<!_CUOS@]/1J^WHP.3WQ>^.F""6'=FRT(\,MG
M7M'UY=\1[XAGB+;@]G_%9^K[.6P<#8H7LQ!PUW<@Y9]]RY);MVWA'X.F14AD
MU2%43. E,0Y0,0Q39@)3%',# (#D(" @(#KSQ()204N""&9PIP ]\._OOT,0
M0"""'!L0<$=#U!W&^##,[OZ .B[>-=U*2UNF=(U.Z YCU9;I8U&S)ESB81<N
MV\80(&57$X\<RTS#2*IA#(39"(#OG#WI,XRX;Y$4&LU,R0@MZK6_MN3RN"4I
M\4F;)%L2IB  "T5GQ5Z'_1]Q@)BM4X>I)-5,"GKM-2*"JYC^&KP$B1.4[$FH
MD322 Y8,8^:\X(^M8LRSBT]WXFHFHB(H0MQHE>(?I)<8!*3WR4ZG(MWBH%S+
MQC4\P3$0#C9 <1+>O#WTE5("9?$6B3%!+!=1IDU*W+ $^JU!0JY<EJE>"V'/
MFCBGZ'P49D[A'B66DDO+HM:D+EA(; KJ1,X$NS T<H$DN;DADUUM!_3$H6-=
M\VV9EJI5XABA(47)1-2IE#BCQCMF3)WSN<XAL%:,2 F8<7CG#BA:=-Z<. M2
MD-3ZP**H6EC*U*3.I2AW_#6DR%J%^5IS>;7IBI^C=Z4-*JP*WA\U](A8/C:1
M4TU<F:S9EH6*A"2P*GDN;C?V644)0=TJ"?52QNE0%:T!)O'4>O'LZTIJ7IMP
M_;ID>IK.&*4NT:F=MTU *F==MRJ0&$I>,&8!C;."M<H=;3J,^@K::MDRIDI"
MIE-/EST)4I$Q82I4M2^4L7Y57N[')TKTC\.:CPY,T:FU+3ZK3JB=35"_!JZ:
M;33"E$V4ATB<A!6D$E)*73MS.&'1=6X??C>KW+,!EWN&W!#DC+VZ/O%9= [D
MX9K%]B+ &X:_5KM!B2>K-W':SAQW+-MU:( Z.XW<-F[%CVN^_1XDQT'[+5Q5
M5L[[5C14>@O454T^2S-++R"Q6D:R"IEV+NLIMXZ4*<Z:4-!%;"F+1-=PLN[!
MNFW.<X!CSWZ8.+M'TWB'@S2=7J%(H=-KOV6:E+DRS-J9GU<F;+TFDE2@P4NK
MK?$"O$4A"42E3%3 E)?U-Z!.!>(-9X5](FMZ%2(FZGJ^FC@31YL^8)%+(^MY
MLF=KE?.GJ]I$N@TU,EC(2N;,F3DRY<M2U!)D;T<] .U-E>X*CJ9%"XUPD2D6
MYYF6A30D,ZR P\P0B_*H$41/_)RD@#E^!B@LV!@8PIA07'OILXEXN\:@TY4W
M0=$5S)]4I9A%95(<@>O5<OD64J#\U-)*)(?D69W(Y]0>C#Z.?"' 8I]3U9,O
MBCB5'+,]>K9(.GT,[E#C3:"9S(!2JZ:NJ\6I*@)DL4[^&'Y@           ;
M   ZMN0 &P/!BE22>KD'+/TRP.;7))O8%@?1&,09AX>K,,\0Q.WO:VQV&[=
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M[@D:4WS+)(,QR <?-'TE\2GBKC/7-52OQ*;UPTE#^***C_:\A27) $X(,\V
MYIRK9 ^P7H@X0'!'H\X;T-<H2ZT4**_5  RCJ6H_MNJ2LL"HR#,12I)N)<A(
MAPN-$?(&#9\V(L+9(VN^V'BRX-7B\.6K[.KUX@>?1K; Y]S7?\N$5FN&DTMN
M$2L%I&6[I71#D;CM*!E+/1T[/I4?::.KV/-5:U85@Q7.O*/*-J)1J[&)8113
M,2O$B$2!%?N<HKBHK8/"VFZ+64,^9J**<SDU12@S:DR5>'X4H@!(F(Y@5%3*
M()YBSL"!6'&VK\1T&I4\G1UU2:=5&B9,\"D3/29QG3DEUJD365R)1[+A@Q:[
MQ"K5/"N\,C0T869K>XUT:.ACNDF1):J;%4A 1@O5R+*(-"OI:W#-J+I9-!<Z
M2 *BJH1%4Q"F*F<2[.CA[AF:ODDT]--7RORRZV8M8 R2E$U18.'-A?,:3.XL
MXSIT!<^JK)2'8*FT$F6ESL%+I4I<W+.Y )V,?FE.%?X9"NXU69H>X]SZRAT7
M:L>K*TK8NCZ@C4WZ*2"Z[%1]$6X>-B/$D7+955L=0%B)+H*'*!%4Q,7P]PW*
M5R3J>FE**>8)F5<U"B'8$!4X$A]\6(V>(D\7<9U"2N15UDY )252J"3,2"P=
M)4BE*06*20[L02+Q,YP,>EWPC-^])NM:0TN)*Y#NW4?9J>GHA*L+1QM"1H5:
MVJZBF+(Z,NSHRG55W814C+@1@9ZH55(RRXMC"W*HGK/%&FZ)24$J9IR9 GFK
MEH4952J<KPC*GJ/L&8MD\R4.IA=@[%HW7@K5^)-0U2?)U==4JF113)B!/HTT
MZ?&$V0E)"TR)3J"%3/9YB"'4U@WR\.]P@&EIH?WNLG2>CQ=9Q;Z JRU<E44_
M'HTS1\X5_,-ZMDHU)V*]1P$NX0$K)%)#DFZJ:(@7CBF)Q,88X1T?3M2HZF;6
M4PGS)=0):%&9-1RH,M*V EK2'!.X)V<  1''W$.KZ-74$G3JQ5-+G4JEK2F7
M)F<R_&6D'[K+60R0![) [/$0T=PGG#8S$>QEHFJ;T2D5)M&[^-DH[1WIYZPD
M6#M(B[1ZQ>-K8*MG31T@HFNV<H*'171.15,YDS 8=F5H/"Z2I)ETB2DE)2JM
MF<P4DL01XX8@V((!!!!P8T]/%'&ZTA:)]>M"@%)4G3I2DJ20X4E0I"% @@@@
MD':/M_7*N'!Z9R^8!T_P;H3QC_:M#9^C Z#PK^)1]OV^K)L,SQ_;'(\2\<M^
MZZA_]MEYV_@@BXG5=S+F07!X3=X'$J]C+P1>B(XN&YFGL4T;2#"X;6THU"XD
M7<(Z8D8-WC:H2G<+QB\<5JDL0S91F"111"KY<BG5KJ*5*4JI5:IX(0"2DR#4
M>&$I6%.099LIWN[G,7).JJJ5PY,K2M2:R7HZJ@K4A(4FH32>(5*EE(2")ERD
MI !L0!%+"DN%_P"%RK]V[84)>*N:U>L6Q7CYI2=G*$J)TS:'5*B5R[;Q%OGB
MS=N98Q$BK*D(F*IBI\;C" 8M29PWPY*8S:23)!)2E4VJG(!(<@.N:F[ VSO:
M\4G)XQXOJ2I-/75,]2;J3*HZ>80D,'(13*(#L'+#':-\_7*N'"'^F[Z#U!^#
M="=FK(;7!XNS'Y?4/"H#B71$EC:N6Y'_ #GWS=AM'8/$W'/\=J/3[VRS;I_B
MD.FT)O= FD70-UHRW&G(FVK6@92:1@9VL1I..HVX=M72RQ6W.<C%0T?$1TW$
M,%C >:C7D4VG&[8%G31^NHV)&.L?JO!M#/D*G:5]QG)EE:)8F*FR:@)!("5+
M6I:%$$E*DK4"IDJ !)&5T/TA:G3UB*770*BF6L2YE1X*)%12DDCG6E"4(F)2
M2!,0I"9@2"M*R1R&WW<RIEXZT%?UE2TDCW2PMO5-34[+M1;O$!6:TR^E8B2;
M"<J[5T@*B;=TB)BJMUR 7C%43,(#6=/*!JY,J8DL9TN6M)L6,P)4D[@@$I<$
M^8L(N*JFE-'43I2KIIILV6M+$6E*6A8<$'90<7W&T4@=%/AZ=,>BK]T%+:2%
MT7-S[(*RX1-PJ:]Y]$Q3YO!R>;-6HHAW3U.Q4@,I3BITI=!GW5R$DFU6CEBE
M[J*JE:^H\(Z7.HYZ**F335?)S29OBSE@K3?PU!2R.69=+L6)"G#,:*TGC_69
M&H4ZM3K%5-"5A%3*,FG2H(7;Q)9ERD*YY7V^5V4Q1?F!B];351P58T]!U92\
MLPGJ:J:)CYZ FXMRF\C9:'E6B3Z.D6+I(QDG#1XT71<(*IB)3IJ%, CGBH9D
MM<E:Y<Q*D3):BA:5)925))!!'5)!!/O9P\7W*FRYTN7.E+3,E34)F2UH(4E:
M%@*2I*@X(4""""Q!BOSP]>FWI-:'331K5T=+EKV\/7;FYJ=5"C3]+3O.I(%.
MC!B0-[Y867!OW(:3?Y=R ARO= @KRG$3XN[<'Z50:D*XUU,)_A"G\/VYDOEY
MO%<^PL._*FZ@2-@#%><?ZYJFCC3/JVJ53>.:H3N67)F<YEBG*'\66MN4+5]D
MA^;VG81*=P=5U:\O?H2:.5V+GSIZFKZN;?H3543RC*/CSR<D>4DFYG!F44U9
M1[<>202)Q&K5!+(G&XG&$PCKNNTLFDU:MIZ= E29,_PY:.8J 2R2W,IR6).7
MLW2-KX;JZBNT/3:NJF>+43Z<+FS"E*2I7,H.4H 2"POR@!\ 1 EPH7#Q7(MM
M=VJ='30R3@6+R@9=U3%;WAE8EG5+M[5[%91E+4_0L&_2=0A6<*](>.=SDFTE
M%9&22<)1C)JU;(R$CN.@<'T\ZEEUVI\ZA.2F9+I4J* F4;H7.4.5;J Y@@*#
M @K422E-?\5<?55+63M-T4(2JF694^L6A,Y2IJ3RKET\I3H 0H%*IBPHJ4"$
M)2$\RXPWO"M\,Y1K$M75'6ET(JGF'<[MQ*5/H^TJRISD5C$!'NY\]MPU9@V<
MB<A"&.Y3!43E!,_&,0<9X</\,33X:)%,M2G $NMFE>'LE,YW R+C)O&K+XMX
MTD@3IE15IEH4DJ5-TZ2F4Q( "E*I4I8DAO:#N-HL9\$5PNJ&GHA-6CNW"PM'
MZ0U&P@3W&@3*-Z9N13+91NTD)R$8NUEW$1.13IP@,W @NZ;&:N492,7*U!ZR
MC-(XEX:^I^6II5*7135\C+#S*>87Y9:R![:%APE9#NZ5 D@FR>#^,/K\3*.L
MEHDZE)E^)[#)E54H$)5,EI))0M!*3,EAT@*"D%N9*+ &8=OB'[,:G[74_!/Z
M8WN-/=?&7'Y=;\X;$'[1QM?X6-^W3O87A'ACCU #XZ]7+V?MMC=@80GAV;=_
M$/;X<3U#;FUF&;[^70=1:$+X-FS[M_-B#Y@OUZ.7O9\?$N+WA";-NSK].>_3
MLU8DLUFQBYZ6?)V8;,;L""A=N_V8"ULM[A]J[O[KL_7$(,,V+;VPP#X)[]'L
M.S0B#7A:OQWM)VTK-_UN3?OX]D?1A^\W$_3ZSH^[CU-;]<E[6\@8^?\ ],G]
M\/!K9^I:_P"/KZ(B)QZC9[V?WYL#\&_NW\8.UKW\A;(=MR_]^SK="RU(W<TA
MJ&A'3074!!O#5?4@F()T2Q-/"5V1%P :N2D9(&$68!'7W;F("4!Q6GI;XF_8
MOP-K%9*F^%6U<@:70 *9?K->\HJ2Y!YJ>G\:I!%WDMY7!Z"^#_V:>DKA_3IT
MGQM.H:@ZUJOLO+]2TOEGA"RS<E55"GHR"6:H[1:3 ,M6/F^25%QDY%W/7%R_
MYSL''UO^4&^XY#@Y/NN[)<B[N"<@O^7,(/T:_7LU8EF#[6+.P>P=]O[B>D(3
M(.H-?C$=8CO]F!)O=NN#@LY[L68=.C,B ;W2  !P?D'ED #I#VZS_P!E[AY?
M!V9:A'M].Y<#$G5YCD_XE/WS]TI]A;!9NM\Q7WI*+</2_P#:5-;K]RJ1G;/7
M=[QA_<UH .@77@:M6DU7O?R_4^M3ZQ\?;KQSX\MJ\AOY @9/\HG^=V%L&]KY
MX>C,?]@U)_\ FD\/_NU);YDM[XL(@ 9Z@#P:O /I]6K/&E$X!OAQ@>9-\&Q
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M#??>9O\ M*?M8?=:?'Z_GBO?27^]^5_M*F?R\.H?Y1AO<UN7X!=>]NDW7O\
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MN4XHF!*S-8\Q3+4J6H2PP6ZN<E(*3>9OF !9&\(%   +6W        *3E@
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M+ ^VL5=2"++1/EJ .3(MBA"SVL6:]FN!U.S@_%H].0>KQ=.^7>QR>VUQ8&[
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M8V-KOYH7Q9^/[,1<,0"P OYL>XL3T_3"#"]_<]LDOTMY&]V.#9!A<$/M?RN
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M7\I/V6'(.I[X+][C]?>80<SMOG%_*3]:6 2 7_1^8#]>\(.9VWSB_E)^RPY
M2]_ET9\9W\X0<SMOEK^4G[+ ) P3\OT7;9X0<SMOG%_+3]EARCN?-OT;W?S)
MS>$',[;YQ?RD_98<H[]^^<[G/6^[P@YG;?+7\I/V6'*/+=K-\P?AB$',[;YQ
M?RD_98<H[X;/N^./@(0<SMOG%_*3]EAR!W+G]<VWA!S.V^<7\I/V6'*'>^UM
MK=F_5S"#F=M\M?RD_98%(/78>X;7?]??"#F=M\M?RD_98<HZFQ)VWSLS'R^4
M(.9VWSB_EI^RPY1U/R_1"#F=M\M?RD_98<H[_*WE:S[[=H0<SMOEK^4G[+#E
M'4_*UWLPZP@YG:_+7Z?^&GT_ZK#E'4[=-L;?.$',[;YQ?RD_98<@[OU?X_'^
MZ$',[;YQ?RT_98!('5^MG_)[^YR]X0<SMOG%_*3]EB.0=3\?[(0<SMOEK^4G
M[+$\HZD8PS6:[,VT(.9VWRU_*3]EAR#O\OT?,7[P@YG;?.+[,L^.GGX^2PY1
MU/R;(+,S,X_3"#F=M\XOW^,GT?ZK?HP"0/R-M_;[WA!S.V^6OY2?LL1R#O\
M+]$(.9VWSB_EI^RP* >OR_1^6$',[;Y:_E)^RQ/+W/5WO^3SMBYA!S.V^<7\
MI/V6!2#U_4ON[^^$',[;Y:_E)^RPY1>YOF^?E"#F=M\XOY2?LLO5@$@?H./[
5<[O"-MYM;]:GC)[/$L._Q/Z81__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
